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The investigation of a biological system can be probed in multiple fashions 
to improve our understanding of how they work. The work presented in this 
dissertation demonstrates how my work utilizes synthesis and spectroscopy to 
probe biological systems and gain a deeper understanding of cellular processes.  
My abilities as both an organic and analytical chemist are displayed throughout 
the projects that I have worked on throughout my graduate studies. Real 
advances have been made in the probed biological systems, allowing future 
researchers to take a more targeted approach from the chemical knowledge 
presented.  
Chapter 1 will focus on the degradation of dichloromethane in two 
members of the Peptococcaceae family. Initial isotope analysis of the 
degradation of DCM anaerobically suggests that each bacterium have a unique 
mechanism to convert DCM to non-toxic byproducts. An NMR analysis study 
using 13C-DCM is applied to both pure culture Dehalobacterium formicoaceticum 
and the mixed culture consortium RM containing DCM degrader Candidatus 
Dichloromethanomonas elyunquensis to observe the degradation and 
subsequently perform a pathway analysis.  
Chapter 2 is a study on the induction of diabetes that is associated with 
the prolonged treatment of inflammation with glucocorticoids. These drugs have 
wide ranging applications due to their global anti-inflammatory properties 
although they tend to limit the secretion of insulin in β [beta]-cells located in the 
pancreas. To gain a better understanding of this effect a library of glucocorticoids 
containing both steroidal and non-steroidal scaffolds were synthesized, 
characterized, computationally modeled, and tested in-vitro as potential anti-
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Human life has transformed drastically since the events that led to the scientific 
revolution and the emergence of modern science. During the time science was 
divided into disciplines of astronomy, biology, mathematics, physics and 
chemistry. The initial research of these disciplines changed the way society 
viewed nature, disease and life in general. Scientific discoveries at the time had 
monumental impacts on life in general but maybe most importantly in diseases 
and human anatomy. Monumental scientific discoveries can still effect societal 
views todays in a positive matter. The work presented herein show investigations 
into biological systems using very different interdisciplinary approaches. They 
share a common investigation into problems that were created by humans. The 
first chapter will detail the approach taken to solving the problematic 
bioremediation of dichloromethane in our ground and drinking water supplies. 
The second chapter will entail an investigation into solving the harmful side-
effects caused by the long term use of glucocorticoids. The experiment will 
provide information into the structure-activity relationship the glucocorticoid 
ligand-glucocorticoid receptor play in the design of a dissociated steroid, one that 
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Dichloromethane (DCM) is a frequently used industrial solvent that has been 
found to be a probable human carcinogen and frequently found as a contaminant 
in groundwater. It is toxic to the ecosystem and its volatility causes stratospheric 
ozone layer depletion. The degradation of DCM aerobically is done by harboring 
glutathione-dependent DCM dehalogenases, although build up DCM in 
groundwater exists in oxygen deprived environments and little is known about 
anaerobic DCM degradation. Two members of the Peptococcaceae family were 
found to degrade DCM anaerobically. Initial isotope analysis of the degradation 
of DCM by the two bacteria suggests they each have a unique mechanism to 
convert DCM to non-toxic byproducts. An NMR analysis using 13C-DCM is 
applied to both pure culture Dehalobacterium formicoaceticum and the mixed 
culture consortium RM containing DCM degrader Candidatus 
Dichloromethanomonas elyunquensis.  
1.2 Introduction 
1.2.1 Chlorinated solvents 
Chlorinated solvents were first discovered over 100 years ago and were 
commonly used by the 1940’s. Since that time, chlorinated solvents and their 
degradation products have become the most extensive organic contaminant 
found in groundwater of the United States.1 Chlorinated solvents are used across 
an array of industrial and commercial applications as well as many consumer and 
household products. The properties of the solvents have resulted in many uses. 
Chlorinated solvents are roughly all nonflammable and noncorrosive, in addition 
to being exceptional degreasing agents. The degreasing properties of the 
solvents are used to clean everything from clothing to electronics to large 
manufacturing equipment. Dichloromethane (DCM), trichloroethane (TCE), 1,1,1-
trichloroethane (TCA), and carbon tetrachloride (CT) are some of the most 
commonly used chlorinated solvents.1 Once these solvents are released into the 
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environment, they have the tendency for widespread contamination due to their 
physical and chemical properties.2 A number of treatment technologies have 
emerged the one to prove most successful thus far involve the use of biological 
degradation. Research in the 1980’s provided the first documentation of common 
chlorinated solvents TCE, TCA, and CT could be biodegraded by 
microorganisms that are present in groundwater and soil.3-6 The bioremediation 
industry at the time did not have a complete understanding of the microbiological 
process and what individual bacteria where involved.7 It was not until the early 
1990’s that bacteria were being discovered that were degrading specific 
chlorinated solvents.8 
1.2.2 Dichloromethane in groundwater 
Dichloromethane is one of the smallest chlorinated solvents found as a pollutant 
in groundwater and soil. It was first synthesized in 1840 by V. Regnault who was 
able to use light to chlorinate methyl chloride.9 It is a colorless, neutral, highly 
volatile liquid with a hint of a sweet smell. DCM is nearly nonflammable in the air, 
it only becomes flammable under a limited number of oxygen-nitrogen 
combinations.9 That makes DCM unique when compared to chlorinated solvents 
as it’s the only one with a low boiling point and nonflammable.  The vast majority 
of the DCM in the environment is due to anthropogenic activity, although small 
amounts are produced naturally in the oceans, soils and wetlands or through 
volcanic activity and emissions.1 DCM is used as an industrial solvent, synthetic 
intermediate, dry-cleaning solvent, degreasing agent in electronics, 
manufacturing and industrial machine maintenance.10 Due to its vast use, 
accidental releases and ill-advised disposal practices DCM can be found in large 
concentrations near industrial areas.11 In residential areas it is commonly 
detected in the soil, groundwater and drinking water wells in the United States 
(U.S).12 DCM was found in concentrations from 0.02 to 100 μg L-1 (ppb) across 
groundwater in the U.S. The Environmental Protection Agency (EPA) registers 
DCM as a priority contaminant and is has listed the solvent as a probable human 
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carcinogen and can cause kidney and liver damage.11, 13 In addition to polluting 
the ecosystem, it can cause stratospheric ozone destruction and is a potent 
greenhouse gas.14 The released DCM into the environment causes the solvent to 
migrate through the soil and assembles as a dense liquid that doesn’t dissolve 
into the water and sits as a layer at the bottom of polluted aquifers.15 In situ 
bioremediation efforts to detoxify the contaminated sites have proven efficient 
and at a relatively low cost.  
1.2.3 Degradation of dichloromethane  
The degradation of DCM under nitrate-reducing and oxic conditions is well 
documented and has been studied in detail.16, 17 The degradation is mediated by 
facultative bacteria and aerobes containing glutathione-dependent DCM 
dehalogenases that leads to complete detoxification to carbon dioxide (CO2) and 
inorganic chloride (Cl-).6, 18, 19 The aerobic bacterium Acinetobacter sp. was 
isolated from activated sludge that grows on DCM as the only source of organic 
carbon and energy under nitrate-reducing conditions.20 Methylotrophic bacterial 
strains Hyphomicrobium, Methylobacterium, Methylopila, Methylophilus and 
Methylorhabdus spp. were all found to degrade DCM under aerobic and nitrate-
reducing conditions.18, 21 The main complication with the application of aerobic 
bacteria for bioremediation of groundwater is the low dissolved oxygen 
concentration found. Therefore, bioremediation efforts have turned to anaerobic 
biodegradation as a preferred strategy for clean-up of polluted aquifers. 
The anaerobic degradation of DCM under anoxic conditions is far less 
understood than aerobic degradation. Unlike bacteria that degrade DCM 
aerobically through direct hydrogenolysis (i.e. reductive dechlorination), rather 
DCM is channeled into the Wood-Ljungdahl pathway or reductive acetyl-CoA 
pathway broken into hydrocarbons and inorganic chloride.22 Dehalobacterium 
formicoaceticum, affiliated with the Peptococcaceae family is the only pure 
culture identified to metabolize DCM via a fermentative pathway producing 








The second bacterial strain to be found to degrade DCM under anoxic conditions 
was discovered within a mixed culture harboring organism affiliated with the 
Peptococcaceae family, e.g., Dehalobacter sp. and/or Dehalobacterium sp24. The 
mixed culture, consortium RM was derived from pristine Rio Mameyes River 
sediment collected close to the El Yunque National Forest in Puerto Rico.25 The 
DCM-degrading bacterium in the mixed culture was identified as Candidatus 
Dichloromethanomonas elyunquensis, leading to a new genus and species in the 
Peptococcaceae family which metabolizes DCM to acetate, H2, CO2 and Cl
-
.(Figure 2)26-29 The two organisms D. formicoaceticum and Ca. 
Dichloromethanomonas elyunquensis appear to use similar mechanisms for the 
degradation of DCM under anoxic conditions through fermentation pathways.8, 25, 
29 Past studies on D. formicoaceticum and Ca. Dichloromethanomonas 
elyunquensis proposed a degradation funneling DCM into the Wood-Ljungdahl 














The proposed degradation of DCM begins with the removal of the chlorine as 
hydrochloric acid. The carbon from DCM will then find its way onto methylene 
tetrahydrofolate (CH2=THF) where it can be inserted into the Wood-Ljungdahl 
Pathway. 3 equivalents methylene tetrahydrofolate molecules enter the pathway 
and two thirds is oxidized to formate forming formyl tetrahydrofolate (CHO-FH4). 
The other third of methylene tetrahydrofolate is reduced to acetate with the 
addition of carbon dioxide.  
Past experiments of D. formicoaceticum and Ca. Dichloromethanomonas 
elyunquensis have been able to determine the byproducts resulted from DCM 
fermentation although the removal of the chlorine mechanism has not been 
resolved. It remains a challenging task to study the bacteria due to the anoxic 
conditions in which the bacteria are grown and studied. To determine the 
mechanism of the removal of chlorine and subsequent intermediates it is 
imperative that the system is observed in a closed system to control the growth 
environment. 
Researchers are challenged with the task of providing concrete evidence that 
bioremediation will lead to detoxification. Decreasing toxic pollutants or 
contaminants concentrations are not always an absolute measure of the 
bioremediation effort due to processes like adsorption or dilution being factors 
behind the observation. The discovery of the mechanism for the removal of 
chlorine can aid in the optimization of remedial strategies.  
1.2.4 Targeted NMR spectroscopy  
Nuclear Magnetic Resonance (NMR) spectroscopy offers techniques that could 
possibly elucidate the pathway in the degradation of DCM in D. formicoaceticum 
and Ca. Dichloromethanomonas elyunquensis. NMR does not have near the 
sensitivity as mass spectrometry, although it does have its advantages through 
its ability to quantify metabolites in a biological system with little need for sample 
preparation or fractionation.30, 31 The minimal amount of preparation needed for 
NMR leads to an observation window into the changing metabolome in vivo. The 
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use of stable isotope labels can be used to study the mechanisms and dynamics 
of metabolite transformations. Therefore, infusion of a 13C-labeled substrate, like 
13C-DCM feed to the bacteria can allow for the detection of all 13C-metabolites 
that are the degradation products of the DCM fermentation.  
There are multiple NMR experiments that can be used to elucidate pathway 
mechanisms. One or two-dimensional methods can be used as well as detecting 
specific nuclei in a biosystem. One dimensional (1D) 1H-NMR is commonly used 
due to the abundance of hydrogen in a biosystem, the sensitivity of the 
experiment and the ability to quantify metabolites. The experiment has answered 
many relevant questions in metabolomics using standard 1H-NMR databases to 
fit experimental spectra to identification and quantification of metabolites.32-35 13C-
NMR has a larger spectral range, typically over 220 ppm compared to the typical 
10 ppm in 1H-NMR. This aids in the spectral resolution if there are many signals 
in the 1H-NMR that begin to overlap. 13C-NMR does indeed suffer from a low 
sensitivity due its natural abundance (1.1%), which is more than 8 times less 
than 1H-NMR. However, the low natural abundance of 13C can be turned into an 
advantage using stable isotope labels. Isotopically labeled 13C has seen many 
applications in NMR spectroscopy for multiple biosystems including elucidating 
the human brain amino acid labeling with 13C-glucose. 36-39 Two dimensional (2D) 
NMR methods are used for coupling nuclei for the unambiguous identification of 
metabolites in a sample.40 Common methods used today are 1H-1H COSY 
(correlated spectroscopy), 1H-1H TOCSY (total correlation spectroscopy), 1H-13C 
HSQC (heteronuclear single-quantum correlation), and 1H-13C HSQC 
(heteronuclear single quantum coherence or heteronuclear single quantum 
correlation experiment). There are software’s that can be used to match 
experimental spectra for metabolite or compound identification.41  
Stable isotope tracing is without a doubt the most useful technique when 
elucidating mechanisms or transformations within a biosystem. The isotope can 
be traced through 1D 13C-NMR due to its increased sensitivity but can also be 
traced in 1H-NMR using an indirect 1H-[13C] NMR method. This method is used to 
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detect protons that are directly attached to a 13C nuclei. The larger gyromagnetic 
ratio of protons is the reason for this effect. With the 1H-NMR spectrum, signals 
can be detected for binding to both 12C and 13C nuclei leading to the ability to 
calculate the in vivo enrichment of labeled metabolites.  
1.2.5 Targeted mass spectrometry 
As previously mentioned mass spectrometry is another technique commonly 
used to probe metabolic pathways typically used in tandem with separation 
techniques that precede the detection. Liquid chromatography is by far the most 
used separation method in biological systems. Liquid chromatography – high 
resolution mass spectrometry (LC-HRMS) can detect thousands of metabolites at 
concentrations in the nano molar range with very good resolution.42, 43 NMR and 
MS used together for the study of a pathway because of the different answers 
each technique can solve. Using a stable labeled isotope with MS can measure 
multiple isotopes of the same molecule simultaneously. NMR has to the ability to 
measure multiple isotope species of the same molecule although the more 
labeling occurring in the sample and the spectra will get very complex and signal 
begin to overlap, decreasing the resolution of individual peaks. Targeted MS 
studies using a stable isotope label have been essential to probing biological 
pathways and discovery significant molecular markers.44-47  
1.3 Material and Methods  
1.3.1 Cultures, cultivation conditions and experimental setup 
Chemicals 
DCM (purity>99.95%) was purchased from Acros Organics (Thermo Fisher 
Scientific, Fair Lawn, NJ, USA). 13C-labeled DCM (99 atom % 13C) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC grade propanol, 
pyridine, propyl chloroformate (PCF), and hexane were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All other chemicals used were analytical reagent 
grade or higher, unless otherwise specified. 
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Microorganisms and cultivation 
Culture RM, harboring DCM-degrading Ca Dichloromethanomonas elyunquensis, 
was enriched from freshwater sediments.25 After establishing the enrichment 
culture, culture RM was maintained in the laboratory as active cultures by 
repeated transfers in fresh medium with DCM as the sole substrate. D. 
formicoaceticum was obtained from American Type Culture Collection (ATCC 
700118). Both D. formicoaceticum and culture RM were cultivated in 
bicarbonate-buffered (30 mM, pH 7.3) anoxic basal salt medium and the routine 
cultivation was performed as described previously.29, 48 
 
Analytical methods 
DCM and methane were measured by manual headspace injections (0.1 ml) into 
an Agilent 7890A gas chromatograph (GC) (Santa Clara, CA, USA) equipped 
with a DB-624 column (60 m length, 0.32 mm i.d., 1.8 mm film thickness) and a 
flame ionization detector (FID). The GC inlet was maintained at 200 °C, the GC 
oven temperature was kept at 60 °C for 2 min followed by an increase to 200 °C 
at a ramping rate of 25 °C min–1, and the FID detector was operated at 280 °C. 
Acetate and formate were measured using an Agilent 1200 series high-
performance liquid chromatography (HPLC) system equipped with an Aminex 
HPX-87H column (Bio-Rad, Hercules, CA, USA) and a UV detector set to 210 
nm. The separation occurred at a column temperature of 30 °C, and the eluent (4 
mM H2SO4) was delivered isocratically at a rate of 0.6 ml min
–1 for 25 min. 
For acetate analysis, a volume of 800 µl culture samples were taken using N2-
flushed syringes and centrifuged to remove cells. The derivatization of acetate to 
propyl acetate was performed as described previously.34 In brief, 800 µl sample 
was mixed with 500 µl of propanol/pyridine mixture solvent (v/v = 3 : 2) in a glass 
vial and 100 µl of PCF was subsequently added. The resulting mixture was 
vortexed briefly and the derivatization reaction proceeded under ultrasonication 
for 1 min. After derivatization, the derivatives were extracted with 300 µl of 
hexane, which was undergone GC-MS analysis. GC-MS analysis was performed 
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using an Agilent 7890A gas chromatograph (Santa Clara, CA, USA) equipped 
with a DB-624 column (60 m length, 0.32 mm i.d., 1.8 mm film thickness) and an 
Agilent 5975C inert XL MSD with a Triple-axis detector (Santa Clara, CA, USA). 
The GC inlet was maintained at 200 °C, and the GC oven temperature was kept 
at 60 °C for 2 min followed by an increase to 90 °C at a ramping rate of 5 °C min–
1 and then another increase to 200 °C at a rate of 25 °C min–1. All samples were 
stored at 4 °C in the dark until mass spectrometry and NMR analysis. 
1.3.2 NMR experimental setup of Ca. Dichloromethanomonas elyunquensis 
All the compounds used are commercially available and were used without 
further purification. The NMR sample was prepared in a glove box under argon 
gas. The NMR tube used was a custom order from New Era Enterprises, Inc 
featuring an outer 5-mm diameter tube with a septum screw tip and a separate 
inner tube with cap. 13C-DCM was fed to the bacterial culture directly prior to 
insertion into NMR tube. The bacteria culture was transferred into the outer NMR 
tube followed by insertion of inner NMR tube containing D2O with internal 
standard 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS). All NMR spectra was 
acquired using an Inverse probe on a liquid state Varian VNMRS 600 MHz. 1H-
NMR was acquired with a pulse sequence that included a pre-saturation of the 
H2O signal. For all 2D spectra acquired (
1H-13C) HSQC and (1H-13C) HMBC a 
pulse sequence was used for the saturation of the H2O signal. All processing of 
the NMR data was done using MestReNova NMR software. All spectra were fit 
and normalized to the internal standard peak at 0 ppm.   
1.3.3 NMR experimental setup of D. formicoaceticum 
All the compounds used are commercially available and were used without 
further purification. 13C-DCM was fed to the pure bacterial culture and nearly 
completely metabolized prior to extraction. The NMR tube used was a custom 
order from New Era Enterprises, Inc featuring an outer 5-mm diameter tube with 
a septum screw tip and a separate inner tube with cap. The bacteria culture was 
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transferred into the outer NMR tube followed by insertion of inner NMR tube 
containing D2O with internal standard DSS. All NMR spectra was acquired using 
an Inverse probe on a liquid state Varian VNMRS 600 MHz. 1H-NMR was 
acquired with a pulse sequence that included a pre-saturation of the H2O signal. 
For all 2D spectra acquired (1H-13C) HSQC and (1H-13C) HMBC a pulse 
sequence was used for the saturation of the H2O signal. All processing of the 
NMR data was done using MestReNova NMR software. All spectra were fit and 
normalized to the internal standard peak at 0 ppm. 
1.3.4 Extraction of D. formicoaceticum fed 13C-DCM for metabolomics 
analysis 
The untargeted UPLC-HRMS study of D. formicoaceticum extracted culture fed 
isotopically labeled 13C-DCM for the detection and identification of 13C labeled 
amino acids. The pure culture of D. formicoaceticum previously mentioned was 
passed through a filter for cell collection and kept frozen on dry ice until 
extraction. The frozen filter was then placed in an empty petri dish and 1.3 mL of 
cooled extraction solvent was placed on top of the filter. The extraction solvent 
was made up of 40:40:20 ACN: MeOH: H2O with 1% formic acid. The filter was 
left for and extraction period of 15 minutes at -20 °C. The filter was then removed 
from the petri dish and washed with extraction solvent. The filtrate was then 
placed in an Eppendorf tube and centrifuged for 5 minutes. The resulting 
supernatant was transferred to a 1-dram vial and the contents dried under 
nitrogen. At 4 °C, the remaining solid biomass was resuspended in 300 μL of pre-
chilled MiliQ water and transferred to an autosampler vial. 
1.3.5 Untargeted metabolomics using UPLC-HRMS of D. formicoaceticum 
extraction  
The autosampler vial was placed on an autosampler tray at 4°C. 10 μL of the 
aliquot was injected through a Synergi 2.5-micron reverse Synergi 2.5-micron 
reverse phase Hydro-RP 100, with a 100 x 2.00 mm LC column (Phenomenex, 
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Torrance, CA) kept at 25 ˚C. The eluent was imported into the MS via an 
electrospray ionization source conjoined to an Exactive™ Plus Orbitrap Mass 
Spectrometer (Thermo Scientific, Waltham, MA) through a 0.1 mm internal 
diameter fused silica capillary tube. The mass spectrometer was run in full scan 
mode with positive ionization mode with a window from 85 – 1000 m/z. with a 
method adapted from Lu et al., 2010 49.  The samples were run with a spray 
voltage was 3 kV. The nitrogen sheath gas was set to a flow rate of 10 psi with a 
capillary temperature of 320˚C. AGC (acquisition gain control) target was set to 
3e6. The samples were analyzed with a resolution of 140,000 and a scan window 
of 85 to 800 m/z for from 0 to 9 minutes and 110 to 1000 m/z from 9 to 25 
minutes. Solvent A consisted of 97:3 water: methanol, 10 mM tributylamine, and 
15 mM acetic acid. Solvent B was methanol. The gradient from 0 to 5 minutes is 
0% B, from 5 to 13 minutes is 20% B, from 13 to 15.5 minutes is 55% B, from 
15.5 to 19 minutes is 95% B, and from 19 to 25 minutes is 0% B with a flow rate 
of 200 µL/min. 
Files generated by Xcaliber (RAW) were converted to the open-source mzML 
format 50 via the open-source msconvert software as part of the ProteoWizard 
package 51. Maven (mzroll) software, Princeton University 52, 53 was used to 
automatically correct the total ion chromatograms based on the retention times 
for each sample. 53, 54  Metabolites were manually identified and integrated using 
known masses (± 5 ppm mass tolerance) and retention times ( ≤ 1.5 min). 
Unknown peaks were automatically selected via Maven's automated peak 
detection algorithms. Isotopic ratios were calculated using Excel 2010.  
1.4 Results  
1.4.1 Byproduct analysis of consortium RM in vivo culture  
The 13C-labeled DCM that was fed to the mixed bacterial culture was degraded 
completely over a span of 22 days. The degradation was primarily tracked by 1H-
NMR as it is the most sensitive technique and took the least amount of time to 
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observe the 13C-DCM signals. The analysis of the byproducts of the 13C-DCM 
degradation was complicated by consortium RM containing numerous bacterial 
strains within. It could not be concluded if the byproducts observed were the 
direct degradation product of the DCM degrader in the mixed culture Candidatus 
Dichloromethanomonas elyunquensis or another bacterium in the mixture. The 
prominent byproducts observed were carbon dioxide and acetate. Methanol and 
methane observed but in small quantities. (Figure 4, Figure 5) 
The presence of the methane can be explained due to the consortium RM culture 
previously found to contain methanogens or methane gas producing bacteria.28 
The determination of the byproducts produced was done with the help of arrays 
made from the NMR spectra acquired. The individual peaks were identified 
searching NMR chemical shift databases. (Figure 6, Figure 7) 
The 13C-DCM proton signal is split into a doublet when observing the signal in the 
1H-NMR spectra due to heteronuclear scalar coupling. A non-isotopically labeled 
carbon will produce 1H-NMR signals with small sidebands appearing in the most 
intense signals in a spectrum. These sidebands are due to the 1.1% naturally 
abundant 13C nuclei.  All of the peaks identified in the spectra where aided by 2-D 
(1H-13C) HSQC NMR for peak confirmation. (Appendix 1.6.1) 
1.4.2 Isotope analysis of consortium RM  
The isotope analysis of the 13C was done using both 1H and 13C-NMR. 13C-NMR 
spectra taken over the 22 days (Figure 6) displaying the DCM singlet at 53 ppm 
reducing in intensity. The peaks at 160 ppm and 124 ppm both grew in intensity. 
The carbonate peak was expected as it makes up part of the buffered aqueous 
buffer. The peak at 124 ppm was identified as carbon dioxide after 2D 
experiments (1H-13C) HSQC, (1H-13C) HMBC, (13C-13C) DEPT. (Appendix 1.6.1) 
From the 13C-NMR data it is clear to assume the 13C-DCM carbon has ended up 
on carbon dioxide. The carbon dioxide is in equilibrium with the carbonate within 
the closed system therefore it’s assumed the label was exchanged onto the 
















Figure 7: 13C-NMR stacked analysis of mixed culture Consortium RM after feeding 13C-DCM
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produced by 13C-DCM at 5.3 ppm and 5.5 ppm through its degradation or drop in 
intensity over time. The absence of a doublet produced in the byproducts 
detected was further evidence the labeled 13C ended up on carbon dioxide.  
1.4.3 Pathway analysis of consortium RM  
The NMR spectra concluded through isotope analysis that the 13C label from the 
isotopically labeled 13C-DCM fed to the mixed culture consortium RM resulted in 
13C-CO2. Previous literature suggested that the DCM was metabolized or 
fermented through the Wood-Ljundahl pathway (i.e. reductive acetyl-CoA 
pathway) although the exact mechanics of how the molecule enters the pathway 
is not understood. Figure 8 summarizes the tracking of the labeled 13C-DCM as it 
is metabolism in the Wood-Ljundahl pathway. The 13C-DCM enters the pathway 
and the chlorines are removed as HCl, the remaining CH2 is bound to 
tetrahydrofolate (FH4) forming (CH2= FH4). The CH2= FH4 molecule is found only 
to take the formate branch. It was understood that the CH2= FH4 entered the 
pathway and two-thirds of it is oxidized to formate and one-third reduced to form 
acetate in combination with CO2.
24 Isotope analysis of this experiment proved 
otherwise as no labeled acetate molecule (13C-CH3COOH) was found and only 
13C-CO2 was detected. The intermediates in the pathway were not detected as 
their turnover rate or concentration was under the limit of detection. Future 
experiments on the mixed culture Consortium RM will be aimed at slowing the 
metabolism down by scanning the culture using variable temperature NMR to 
cool down the probe and sample while scanning. The scanning will focus on the 
acquisition of data aimed at detecting only the bonds containing the 13C-1H 
signal, while dampening the signal produced by the naturally occurring 12C-1H 
signals.  
1.4.4 Byproduct analysis of pure culture D. formicoaceticum 
The analysis of the culture containing D. formicoaceticum was analyzed using 




Figure 8: Isotopic tracking of 13C carbon label from 13C-DCM fed to 
consortium RM  
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culture had nearly consumed all 13C-DCM prior to analysis and could only be 
detected with long scan times. The byproducts detected in the culture were 
methanol, acetate, carbonate and glycine with certainty in the 1H-NMR and 13C-
NMR. (Figure 9) 
The peaks were identified with the aid of 2D (1H-13C) HSQC. (Appendix 1.6.3) 
1.4.5 Isotope analysis of pure culture D. formicoaceticum 
The isotope analysis of the degradation of the 13C-DCM signal was tracked using 
both 1H-NMR and 13C-NMR. Due to the heteronuclear scalar coupling effect, all 
1H signals that are bound to a 13C nucleus will appear as a doublet in the 1H-
NMR spectrum. The metabolites that were identified containing an isotope label 
were acetate, methanol and glycine. 13C-NMR was able to identify that the 
carbon labeled on the acetate was indeed the methyl carbon and not the 
carbonyl carbon due to the intensity of the peak at 21ppm. Confirmation of the 
labeled metabolites identified was done using a 1D gradient (1H-13C) HSQC that 
was modified to delete the coupling of the signals in the t2 channel. (Figure 11) 
The resulting spectra displayed bonds generated from an isotopically labeled 
carbon originating from 13C-DCM degradation. (Figure 12) The labeled peaks 
that were detected in the spectra were DCM, glycine, methanol and acetate. DSS 
was also detected but only due to its high concentration in the internal standard 
when compared to the compounds detected in the culture. The DSS signals 
detected are the 1.1% naturally abundant 13C carbon produced by the molecule. 
The methanol was an expected peak as it was seen in the Consortium RM 
culture and detected in past literature.23 
In addition to the labeled acetate detected, unlabeled acetate was detected in the 
1H-NMR scans. The ratio of labeled acetate/ unlabeled acetate detected was 
1.73. The peak at 2.20 ppm was identified as the unlabeled acetate anion, with 
labeled acetate anion side bands at 2.30 and 2.10 ppm. The isotopic ratio of 
labeled/unlabeled was found to be 1.73 as well leading to the conclusion that is it 




















Figure 12: NMR spectra of 1H-gHSQC (orange) superimposed on 1H-NMR (grey) 
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metabolites identified was found to be methanol 1.34 labeled/unlabeled and 
glycine 2.0 labeled/unlabeled.  
1.4.6 Pathway analysis of pure culture D. formicoaceticum 
The pathway analysis for the metabolism of DCM by the bacteria 
Dehalobacterium formicoaceticum was first published in 1996.8 It was 
hypothesized the DCM would be metabolized into acetate and formate. The 
detection of only labeled acetate in the experiments conducted and the absence 
of labeled formate/ carbon dioxide detected leads to believe that only the acetate 
branch of the wood ljundahl pathway is “activated” during the degradation of 
DCM by Dehalobacterium formicoaceticum. (Figure 13) The experiment 
suggests that DCM is degraded via the Wood-Ljungdahl pathway (i.e. reductive 
acetyl-CoA pathway) under anoxic conditions beginning with DCM entering the 
pathway and subsequent removal of the chlorines occur. The remaining CH2 is 
combined with tetrahydrofolate to form methylene tetrahydrofolate (CH2=FH4). 
CH2=FH4 will then get reduced into methyl tetrahydrofolate (CH3-FH4). The 
methyl tetrahydrofolate can be combined with iron-sulfur proton (CoFeSP) 
forming methyl-COFeSP (CH3-CO-E). The complex can be combined with 
carbon monoxide to produce an acetate group and acetyl-COA. The degradation 
of DCM by D. formicoaceticum is evidently not only restricted to the carbon 
fixating pathways alone as labeled glycine and methanol were detected. Glycine 
is related to the Wood-Ljundahl pathway playing parts in purine biosynthesis, B12 
biosynthesis and menaquinone biosynthesis. The labeled glycine suggests an 
entry point for DCM integration into the Wood-Ljungdahl at the methylene 
tetrahydrofolate (CH2=FH4). (Figure 14) The labeling of methanol remains 
misunderstood how it relates to the degradation of DCM. The observation 
suggests that methanol is formed by a side reaction that is coupled to DCM 
degradation in some fashion. 
Further evidence that dichloromethane was used as the primary growth substrate 




Figure 13: Pathway analysis of pure culture D. formicoaceticum fed 




Figure 14: Proposed pathway for the degradation of DCM in D. 




extracted bacterial culture. 22 amino acids were detected containing a labeled 
carbon with most containing multiple carbon labels. All amino acids that where 
found incorporating the carbon label from the degradation of 13C-DCM are found 
in Appendix 1.6.4. The detection of multiple labeled amino acids signifies that D. 
formicoaceticum is using degraded 13C-DCM for the production of energy and the 
storage of biomass.  
1.5 Conclusion 
The targeted NMR analysis of DCM degraders in the Peptococcaceae family, 
Dehalobacterium formicoaceticum and consortium RM comprising Candidatus 
Dichloromethanomonas elyunquensis, were both shown to degrade DCM. The 
byproduct and isotope analysis of the two bacterium’s ability to degrade 13C-DCM 
led to the conclusion that they use separate pathways from one another. The 
mixed culture Consortium RM was found to degrade via oxidation of 13C-DCM to 
a 13C-CO2 molecule while the D. formicoaceticum was found to degrade the 
labeled by reducing 13C-DCM into acetate primarily. D. formicoaceticum was also 
found to incorporate the degraded 13C-DCM into amino acids, meaning it is using 
DCM as a primary growth substrate and partially storing the biomass in amino 
acids. The discovery can aid future bioremediation scientists set out to identify 
the intermediates within the Wood-Ljungdahl pathway contributing to the 




1.6 Chapter I Appendix 
1.6.1 NMR data for the fermentation of DCM in the mixed culture 


























1.6.2 Metabolite integration values observed during fermentation of DCM in 





























peak identity  Formate DCM DCM 
 
methanol 
peak shift ppm 8.4 5.59 5.29 3.85 3.52 
 
1 0 4.98 4.05 9.61 0 
 
2 0.42 4.41 3.79 13.02 0 
 
4 0.22 3.41 2.72 15.19 0 
 
5 0 3.48 2.72 11.88 0.2 
day 8 
 






























peak identity  
   
acetate 
peak shift ppm 3.07 2.92 2.17 1.89 
 
1 1.5 23.71 0.37 1.53 
 
2 2.2 23.25 0.56 7.04 
 
4 3.4 20.98 1.2 10.49 
 
5 3.5 20.05 2.25 12.21 
day 8 8.8 19.05 3 17.05 
 
9 11.53 15.75 5 22.31 
 
10 11.96 13.48 4.97 23.47 
 
11 12.05 14.08 5.27 24.67 
 
16 11.75 13.48 6.39 31.97 
 
18 12.2 14.61 6.48 32.49 
 






peak identity  
   
methane 
peak shift ppm 1.03 0.90 0.82 0.16 
 
1 0 0 0 0 
 
2 1.43 0.33 0 2.2 
 
4 6.27 4.02 0 5.71 
 
5 8 4 0.2 8.51 
day 8 11 4.75 1.2 12 
 
9 12.21 3.19 2.14 14.33 
 
10 12.64 3.01 2.34 13.87 
 
11 13.2 2.91 2.46 13.73 
 
16 15.75 2.62 3.11 13.9 
 
18 15.98 1.34 3.01 13.95 
 
22 16.59 0.2 2.78 14.03 
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medMz medRt  compound Extract 
90.05556 2.038353 Parent Alanine/Sarcosine 510708.3 
91.05882 2.026313 C-1 Alanine/Sarcosine 403299.9 
92.06223 1.439912 C-2 Alanine/Sarcosine 142617.9 
104.0711 1.998793 Parent Dimethylglycine 134654.2 
105.0743 1.450243 C-1 Dimethylglycine 31548.46 
106.0777 1.262513 C-2 Dimethylglycine 24448.15 
106.0502 1.520555 Parent Serine 114759.6 
107.0532 1.387102 C-1 Serine 15620.98 
116.0709 2.033003 Parent Proline 792988 
117.0742 2.137901 C-1 Proline 1480297 
118.0772 1.666046 C-2 Proline 1425148 
118.0865 2.341387 Parent Valine/betaine 1061125 
119.0898 2.182072 C-1 Valine/betaine 1390479 
120.0932 1.735646 C-2 Valine/betaine 1568923 
121.0965 1.706818 C-3 Valine/betaine 726877.9 
122.1 1.636047 C-4 Valine/betaine 201749.1 
120.0657 1.820965 Parent Homoserine/Threonine 278667.3 
121.0689 1.616055 C-1 Homoserine/Threonine 354903.4 
132.0656 1.560654 Parent Hydroxyproline 99272.32 
133.0688 1.355835 C-1 Hydroxyproline 49368.2 
134.0718 1.350368 C-2 Hydroxyproline 44679 
132.1019 2.593606 Parent Leucine/Isoleucine 246546.3 
133.1053 2.355987 C-1 Leucine/Isoleucine 449267.1 
134.1085 2.333281 C-2 Leucine/Isoleucine 647558.8 
135.1124 2.34501 C-3 Leucine/Isoleucine 535746.6 
136.1147 2.395774 C-4 Leucine/Isoleucine 277009.7 
137.1182 2.231128 C-5 Leucine/Isoleucine 70270.86 
133.0606 1.591805 Parent Asparagine 359195.2 
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134.0635 1.655572 C-1 Asparagine 117703.1 
135.0669 1.214862 C-2 Asparagine 61341.86 
133.097 2.257159 Parent Ornithine 1287999 
134.0996 1.844426 C-1 Ornithine 222552.4 
135.1037 1.72533 C-2 Ornithine 289038.6 
136.1075 1.896127 C-3 Ornithine 134018.2 
137.1095 1.921341 C-4 Ornithine 36055.22 
147.0763 1.95963 Parent Glutamine 161196 
148.0797 1.215922 C-1 Glutamine 230518.6 
149.0824 1.379565 C-2 Glutamine 174261.9 
150.0861 1.488503 C-3 Glutamine 86058.13 
147.1127 2.140954 Parent Lysine 1.65E+07 
148.1156 1.604278 C-1 Lysine 3.99E+07 
149.1193 2.065016 C-2 Lysine 4.28E+07 
150.1228 2.023733 C-3 Lysine 2.33E+07 
151.1262 1.951239 C-4 Lysine 6660024 
148.0603 1.558416 Parent O-Acetyl-L-serine 5.68E+07 
149.0638 1.395571 C-1 O-Acetyl-L-serine 1.27E+08 
150.067 1.557698 C-2 O-Acetyl-L-serine 1.18E+08 
151.0704 1.499365 C-3 O-Acetyl-L-serine 5.21E+07 
152.0745 1.503946 C-4 O-Acetyl-L-serine 1.03E+07 
153.077 1.312515 C-5 O-Acetyl-L-serine 466938.4 
150.0582 2.214891 Parent Methionine 81658.06 
151.0613 2.397193 C-1 Methionine 167435.5 
152.0649 2.387696 C-2 Methionine 152272.7 
153.0683 2.322215 C-3 Methionine 56400.59 
153.0769 1.918978 Parent Xylitol 466938.4 
154.0778 1.243878 C-1 Xylitol 64527.67 
175.1187 2.228052 Parent Arginine 2773770 
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176.1221 2.150203 C-1 Arginine 7109984 
177.1263 1.916884 C-2 Arginine 7668734 
178.1287 2.074697 C-3 Arginine 4005241 
179.1314 2.336709 C-4 Arginine 955246.3 
180.1366 2.24359 C-5 Arginine 80939.45 
176.1029 1.345181 Parent Citrulline 46957.82 
177.1062 1.281175 C-1 Citrulline 45953.77 
189.1232 1.785991 Parent Acetyllysine 2595518 
190.1265 1.570015 C-1 Acetyllysine 8411805 
191.1293 2.184215 C-2 Acetyllysine 1.36E+07 
192.1338 2.130339 C-3 Acetyllysine 1.10E+07 
193.1371 2.031776 C-4 Acetyllysine 5625792 
194.1398 2.122633 C-5 Acetyllysine 1659054 
195.1429 2.051494 C-6 Acetyllysine 281593.9 
241.0306 1.386174 Parent Cystine 1579448 
242.0352 1.527843 C-1 Cystine 118720.3 
245.0778 2.544901 Parent Uridine 1.84E+08 
246.0819 2.513394 C-1 Uridine 2.35E+07 
247.0834 2.655957 C-2 Uridine 1199255 





EVALUATION OF SYNTHETIC GLUCOCORTICOIDS CONSISTING 
OF STEROIDAL AND NON-STEROIDAL SCAFFOLDS FOR 
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Glucocorticoids (GCs) have been effective in medicine for the treatment of 
certain cancers, autoimmune-mediated disorders and management of immune 
response during organ transplantation.  The glucocorticoid receptor (GR) (Figure 
15) is expressed across all mammalian cells and tissues, making it a valuable 
target for drug synthesis. The two major gene transactivation pathways 
glucocorticoids play a role in cells are transactivation and transrepression. A 
glucocorticoid that can separate the two pathways is heavily sought after. Both 
steroidal and non-steroidal glucocorticoids are actively researched and 
developed in hopes of finding a molecule with increased anti-inflammatory 
properties (transrepression) while reducing the long-term side effects 
(transactivation). Previously reported 1-(4-fluorophenyl)pyrazole-based GC 
analogues and steroidal C-21 heteroaryl thioethers acting as GR agonists have 
been shown to reduce IL-6β induced inflammation (transrepression),  but were 
accompanied by an unwelcomed upregulation of  pro-inflammatory genes 
associated with GC-induced diabetes, muscle wasting, and osteoporosis 
(transactivation).55, 56 Discovery of an anti-inflammatory GC with a therapeutic 
profile that minimizes transactivation could greatly influence the treatment and 
prevention of inflammation induced T1DM. In this study, an unexplored series of 
non-steroidal glucocorticoid scaffolds containing 1-(4-substituted phenyl) 
pyrazole-based GC analogues as well as steroidal glucocorticoid scaffolds with a 
2-mercaptobenzothiazole modification were synthesized, purified and screened 
for structure-activity relationships that lead to the desired therapeutic profile. 
Compounds 11aa and 11ab were found to have improved properties, including 
anti-inflammatory efficacy comparable to dexamethasone, as well as reduced 
ability to suppress pancreatic -cell insulin secretion. Repression of IL-1β-
induced inflammation by molecules 11aa and 11ab at 1 µM were comparable to 
dexamethasone at 10 nM, while also having similar GRE activation. Compound 




Figure 15: Glucocorticoid receptor 5NFP 




 DMSO, while dexamethasone reduced insulin secretion 6-fold. Results from the 
biological testing of these compounds suggest this molecular scaffold to have 
therapeutic value in treating inflammation in patients whom require unabated 
insulin function. The steroidal GC scaffold analogues synthesized displayed an 
interesting profile while subjected to the two derivatizations. The 2-
mercaptobenzothiazole modification greatly improved the transactivating 
properties of the steroids although negatively impacted the transrepressive 
properties. The second derivatization with 2-furoyl had the opposite effect 
whereas the addition to the steroid backbone greatly improved the ability to 
repress the expression of cytokines. Compounds 3c and 3d, displayed the most 
promising transrepressive profile while compounds 2b and 2c displayed the most 
favorable transactivating profile.  
2.2 Introduction 
2.2.1 Discovery of glucocorticoids  
In the 1930’s at Princeton University, Wilbur W. Swingle (1891-1975) and Joseph 
J. Pfiffner (1903-1975) had undertaken the task of extracting “the hormone” 
thought to be responsible for the symptoms of Addison’s disease. The extracted 
material was found to be a crude mixture of several compounds and it was not 
until Edward C. Kendall (1886-1972) at the Mayo clinic was able to separate the 
final product from epinephrine and believed it to be “the adrenal cortical 
hormone”. The hormone Kendall was able to  purify was later renamed as 
cortisone, and is now known today as the first discovered glucocorticoid (GC) or 
corticosteroid produced from the adrenal gland.57 Kendall later received the 1950 
Novel Prize for Physiology or Medicine for the discovery of the molecule. 
Interestingly enough, it was not found out until years after the discovery and the 
Nobel Prize given out that the team of Swingle and Pfiffner at Princeton in fact 
did isolate cortisone all along although they failed to recognize it’s biological 
significance.58 The first medicinal application of cortisone came soon after its 
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discovery as it was administered at the Mayo clinic in 1945 for the treatment of 
Rheumatoid Arthritis. Multiple more glucocorticoids were discovered over the 
next decade as it was observed that small manipulations to eight positions on the 
steroid skeleton of cortisone caused varying anti-inflammatory effects. (Figure 
16) 
It was discovered that small alterations to the skeleton of cortisone produced a 
different anti-inflammatory profile with C6, C10, and C16 bringing about the 
largest change. The first analogues of cortisone and hydrocortisone to be 
synthesized and clinically used were metacortandracin and metacortandrolone in 
1954.59 The compounds were later renamed prednisone and prednisolone, 
respectfully. The synthetic glucocorticoids exhibited anti-inflammatory effects 4-5 
times greater than their natural counterparts.60 The synthetic glucocorticoids 
discovered following include fludrocortisone in 1954, triamcinolone in 1956, 
methyl-prednisolone in 1957 and dexamethasone in 1958, all still in use today.61-
64 The term or name glucocorticoid originated from its role in the metabolism of 
glucose, synthesis in the adrenal cortex and the steroidal structure. 
Glucocorticoids are steroid hormones, possessing both anti-inflammatory and 
metabolic effects, synthesized endogenously in the adrenal glands. GCs operate 
by acting as a ligand for the glucocorticoid receptor (GR), located in the cellular 
cytoplasm bound to chaperone proteins. The GR is expressed by nearly all cell 
types, including pancreatic β-cells, and is the product of a single gene, NR3C1, 
that is post-translationally modified to produce functionally distinct subtypes of 
the GR.65 It was discovered that small alterations to the skeleton of cortisone 
produced a different anti-inflammatory profile with C10, C6, and C16 bringing 
about the largest change.  
The first analogues of cortisone and hydrocortisone to be synthesized and 
clinically used were metacortandracin and metacortandrolone in 1954.59 The 
compounds were later renamed prednisone and prednisolone, respectfully. The 
synthetic glucocorticoids exhibited anti-inflammatory effects 4-5 times greater 




Figure 16: Cortisone steroid skeleton. 
 
 
following include fludrocortisone in 1954, triamcinolone in 1956, methyl-
prednisolone in 1957 and dexamethasone in 1958, all still in use today.61-64   
The term or name glucocorticoid originated from its role in the metabolism of 
glucose, synthesis in the adrenal cortex and the steroidal structure. 
Glucocorticoids are steroid hormones, possessing both anti-inflammatory and 
metabolic effects, synthesized endogenously in the adrenal glands. GCs operate 
by acting as a ligand for the glucocorticoid receptor (GR), located in the cellular 
cytoplasm bound to chaperone proteins. The GR is expressed by nearly all cell 
types, including pancreatic β-cells, and is the product of a single gene, NR3C1, 
that is post-translationally modified to produce functionally distinct subtypes of 
the GR.65  
2.2.2 Glucocorticoid bioactivity 
The GR has at least six modes of activation at the cellular level. The ligand-
bound GR (GR-GC) can translocate to the nucleus, whereby it can bind to a 
glucocorticoid-response element (GRE) to (1) induce or (2) suppress gene 
expression; additionally, while in the nucleus the GR-GC can (3) facilitate or (4) 
hinder the actions of other transcription factors. Alternatively, the GR-GC can 
remain in the cytoplasm and (5) increase, or (6) decrease, the activity of proteins 
in the cytoplasm.66 Due to the anti-inflammatory and metabolic-altering effects of 
GCs, along with the ubiquity of the GR, GC-based therapies have been 
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successfully applied to treating a wide range of inflammatory, auto-immune 
disorders, and cancers as well aiding in organ and tissue transplantation.66, 67 
Application of synthetic GCs as a possible anti-inflammatory drug for type 1 
diabetes mellitus (T1DM) and immunosuppressive agent for organ transplants is 
attractive for a variety of reasons. Diabetes is the seventh leading cause of death 
in the United States, affecting 29.1 million people or 9.3% of the U.S. population 
in 2014.68, 69 Diabetes also serves as a major cause of heart disease and stroke 
and is the leading cause of kidney failure, non-traumatic lower limb amputations, 
and new cases of blindness in adults.68 
T1DM is an autoimmune disorder characterized by inflammation and subsequent 
autoimmune-mediated destruction of the insulin-producing β-cells.70 One manner 
of autoimmune β-cell death commonly associated with T1DM occurs through 
insulitis, a process by which β-cell damage and death occur via infiltration by 
macrophages and T-cells due to an accumulation of pro-inflammatory cytokines 
such as IL-1β, IFN-γ, and TNF-α.71-73 Cytokine-mediated inflammation of β-cells 
causes the expression of chemokines CXCL9 and CXCL10, which through 
binding to integral membrane protein CXCR3 signals the recruitment of T-cells 
followed by infiltration and cell death.71, 74, 75  
The ideal GC-based T1DM therapeutic would suppress the autoimmune 
response, which ultimately destroys the β-cells. Moreover, synthetic GCs are 
designed to exhibit a "dissociated profile,” that is - possessing enhanced anti-
inflammatory activity with reduced side effects. Despite incredible beneficial 
properties of GCs, they pose a long list of serious side effects including 
Cushing's disease, metabolic syndrome, osteoporosis, and diabetes. In fact, the 
most common cause of drug-induced diabetes is clinical administration of GCs, 
and the incidence of GC-induced diabetes continues to rise.76  
Two of the six modes of activation for the GR are often focused on as being the 
major contributors of the deleterious and salutary effects. One being the 
translocation of the GR-GC to the nucleus to increase transcription of pro-
inflammatory genes, termed transactivation. The metabolic deregulation caused 
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by the direct binding of the GR-GC to GREs is thought to cause several side 
effects including those already mentioned, as well as hypertension and 
hyperglycemia. The other significant mode of GR activation results in 
translocation of the GR-GC to the nucleus to inhibit the action of pro-
inflammatory cytokines, such as IL-1β, NF-κB, or AP-1, termed transrepression.  
2.2.3 Steroidal vs. non-steroidal glucocorticoid scaffolds  
Glucocorticoids can further be broken down by compounds classes and 
ultimately the targeting receptor. Molecules that selectively target the 
glucocorticoid receptor are commonly known as selective glucocorticoid receptor 
agonists (SEGRAs). Historically the first SEGRA molecules were synthetic 
steroids with a scaffold containing the bound four ring structure. (Figure 17) 
It was not until the 1960’s that molecules targeting the GR that did not contain 
the typical 4-ring steroid scaffold were synthesized.  
The new non-steroidal glucocorticoid scaffolds offered researchers more 
information into the structure-activity relationship between the GR and GC due to 
the limited or already exhausted all manipulations previously done on the 4-ring 
steroid scaffold.  
The steroidal GC scaffold’s described herein were inspired by previous work 








furoyl modification.56 The hydrocortisone analogues synthesized displayed 
moderate inhibitory activity towards transrepression factor IL-6 and a feeble 
induction of tyrosine amino transferase in both rat and human cells.77 The non-
steroidal GC scaffolds described in this work were inspired by a set of molecules 
synthesized with interesting bioactivity. Shah and Scanlan in 2004 developed a 
series of novel arylpyrazole compounds that are ligands of the GC receptor 
(Figure 18).78 The binding affinity of the set of 15 molecules originally 
synthesized by Shah and Scanlan were comparable to prednisolone, 
dexamethasone and cortisol. The repression of various pro-inflammatory genes 
through the direct binding of the GR-non-steroidal GC to transcription factors are 
thought to be responsible for the observed anti-inflammatory effects of GCs 
scaffolds discovery within the last 20 years.79-92 
Different GREs differentially affect GR-GC binding conformation which implies 
that a GR-GC that cannot bind one GRE may be able to bind another GRE 
transcriptional cofactors are dependent on the cell or tissue type, and interactions 









based on the specific target gene. Furthermore, different types and ratios of 
dissociative properties of the GR-GC in terms of tissue type.67, 93-97 Synthetic GCs 
have been shown to improve β-cell development and suppress inflammation 
induced by IL-1β;98, 99 However, they have also been shown to reduce adult β-cell 
mass.100, 101 In this study, a series of novel non-steroidal scaffold, 1-(4-substituted 
phenyl)pyrazole-based GC analogues and a series of steroidal scaffold 2-
mercaptobenzothiazole GC analogues have been synthesized and subjected to 
in vitro assays measuring transactivation and transrepression. The top 
candidates from these assays were further assayed to determine how insulin 
production was affected.  
2.2.4 Biological activity of 2-mercaptobenzothiazole  
Over the past two decades medicinal chemistry began to see a large increase in 
therapeutic agents containing a heterocycle. This is due to the proven utility of 
the compound class. 2-Mercaptobenzothiazole (MBT) (Figure 19) a bicyclic 
compound containing two hetero atoms has shown to be associated with multiple 
biological activities making it a prime compound class for derivatization of 
potential drug targets. Derivatives of MBT have shown to have varying biological 
activities, S-acyl and S-acethydrazide hydrazine possessed antifungal and 
antibacterial activities, 2-(thiocyanomethylthio)benzothiazole possessed strong 
antifungal activity and 2,2’-dithiobisbenzothiazole has been used as an 









The anti-inflammatory activity of MBT has been reported in past literature and 
has shown selectivity specific enzymes. In an effort to target the cyclooxygenase-
2 (COX-2) enzyme a class of pentadecylbenzyl compounds were derivatized with 
MTB and increase selectivity 470-fold targeting COX-2 over COX-1.107 MTB’s 
anti-inflammatory activity was compared to aliphatic/alicyclic rings as derivatives 
in the study of carrageenan-induced hind paw edema in rats. MTB proved to 
have better anti-inflammatory than all heterocycle counterparts.108 MTB was 
previously used targeting the GR as a derivatization agent with excellent 
dissociation profile maintaining efficacy against pulmonary inflammation that also 
lessened side effects of transactivation.98, 109-111 
2.3 Synthesis and Purification 
2.3.1 Synthesis of non-steroidal glucocorticoids  
The total synthesis of all 1-(4-substituted phenyl)pyrazole-based GC analogues 
tested in this study were prepared by a previously described synthesis for a 
series of GC analogues55 with a few modifications made to the published method 
(Figure 20). A simple change of reagent is employed in the conversion of 
secondary alcohol 11 to ketone 12, accomplished using a standard PCC 
(pyridinium chlorochromate) oxidation in place of the costly oxidation with TPAP 
(tetrapropylammonium perruthenate) using N-methylmorpholine-N-oxide (NMO) 
as a sacrificial oxidant. The molecules investigated by Ali et al. (Merck 2004) 
focused on alterations to the R2 moiety while leaving the 4-fluorophenyl R1 group 
as a constant. Changing the identity of R1 was realized through the addition of 
the appropriate phenylhydrazine to β-ketoaldehyde 6, thereby installing the 
desired R1-arylpyrazole moiety (termed “headgroup”). Additionally, to further 
enhance the scope of functionalities examined in our biological evaluation was 
included a cyanomethylene unit as an R2 moiety (termed “sidegroup”) previously 
unexamined in this type of structure-activity experiment. Ideally for reactions that 









Chiral HPLC was not employed in the purification of the GC analogues, but 
rather solely standard bench-top flash chromatography (specific procedure can 
be found in chromatographic methods) and trituration techniques were employed. 
Because of such purification methodology, extra steps towards the production of 
aldehyde 10 and 2° alcohols 11 were taken to prevent co-mingling of molecules 
bearing identical Rf values by TLC analysis.  
Briefly, the total synthesis of the steroid core begins with a Robinson annulation 
of compounds 1 and 2 to form intermediate trione 3, which upon asymmetric 
intramolecular cyclization gives Wieland-Miescher ketone 4. Selective ethylene 
glycol protection of compound 4 leaves the α-β-unsaturated ketone available for 
enolate formation and subsequent addition to ethyl formate, giving β-
ketoaldehyde 6. Addition of the appropriate phenylhydrazine to 6 completes the 
core structure of the 1-(4-substituted phenyl)pyrazole-based GCs as compounds 
7. The acid-catalyzed deprotection of acetal 7 provided synthon 8, which was 
formylated via Wittig reaction to afford aldehyde 10, the essential intermediate for 
the divergent synthesis of all analogues presented in this study. Separation of 
starting material from the product of the one-pot Wittig/hydrolysis sequence from 
ketone 8 to aldehyde 10 was futile. To obtain aldehyde 10 in high purity, the 
intermediate enol-ether 9 was isolated from the Wittig reaction, purified via flash 
chromatography to remove any unreacted starting material, and subsequently 
subjected to hydrolysis conditions to afford compound 10 in sufficient purity to 
proceed with the next reaction.   
Insertion of the sidegroup (R2) into the GC scaffold was achieved through 
generation of the appropriate alkyl lithium reagent followed by addition of 
aldehyde 10, resulting in a series of 2˚ alcohols (11) that were subjected to 
biological testing. Intermediate ketone 12 was obtained through a PCC oxidation 
of 11, and after purification was treated with MeLi to afford a series of 3˚ alcohols 
(13), which were also assayed. Synthesis of undesired byproducts 11ag and 
13ag were attempted using the reaction conditions for generating compounds 11, 
12, and 13. Persistent 1H-NMR impurities of purified target compounds 11ad, 
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11ae, and 11af prompted the need to synthesize a t-butyl analogue of compound 
11. Addition of t-BuLi to aldehyde 10a was achieved using reaction conditions 
described in generating the GC analogues in question - with consideration to the 
overall polarity of the reaction solvent system. The reaction to make 11ag would 
not proceed if the volume of polar organic solvent was ≤ 50% of the total solvent 
volume. Even though t-BuLi is generally a poor nucleophile for additions to 
carbonyl compounds, the reaction of t-BuLi with aldehyde 10 produced a pure 
yield ~25% suggesting a non-negligible amount of 11ag is being produced in the 
reactions affording 11ad, 11ae, and 11af. Compound 13ag could not be 
synthesized under the reaction conditions used for generating the other 
compound 13 analogues, ketone 12ag was recovered from a reaction with 10 
equivalents of MeLi with minimal evidence of 13ag being synthesized – this was 
verified by performing an HPLC analysis of crude recovered material where 12ag 
was detected as the major component, and 13ag was detected as less than 
0.1% of the signal intensity of 12ag. 
2.3.2 Purification of non-steroidal glucocorticoids 
Throughout the synthetic procedure there are purification steps that require 
silica-based flash chromatography. Thin-layer chromatography (TLC) analysis 
typically done using a 25% solution of ethyl acetate (EtOAc) in hexanes, 
visualization of resolved compounds using short-wave ultra-violet (UV) light 
reveals separations that do not seem challenging, but when applied to a flash 
column by routine methods result in poor separation. The best chromatographic 
resolution was obtained using a silica stationary phase and a low-polarity mixture 
of EtOAc in hexanes as the mobile phase. Other mobile phases such as 
petroleum ether/ diethyl ether (PetEt/Et2O), Et2O/pentane, methanol/ 
dichloromethane (MeOH/DCM), or tetrahydrofuran (THF)/hexanes proved to be 
less effective toward the isolation of the target compounds. Dissolution of the 
compounds in halogenated solvents allows for wet-loading concentrated 
solutions to the top of the column but will create unwanted band-broadening. All 
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the compounds purified in this synthesis would dissolve mostly in polar solvents 
that would obscure the chromatography and result in poor separation. It was 
found that the best chromatographic resolution can be obtained by loading 
compounds onto silica, wet-packing the silica column, carefully placing a thin 
layer of sand to maintain column integrity during compound loading, and finally 
loading the vacuum-dried compound-adsorbed silica on top of the sand layer. 
This procedure mimics that of a typical TLC analysis where the compound is 
loaded onto a small section of silica, the solvent evaporates, and then mobile 
phase added.  
The compounds subjected to biological testing in this preliminary study have an 
objective purity ~80% by 1H-NMR analysis, which is due to subtle differential 
intramolecular relaxation effects, as well as the presence of diastereomers of the 
final compounds. For compounds bearing R2 = 2,3-diflouoroanisolyl, 3-thiophenyl, 
and cyanomethyl - a single byproduct could not be removed by the 
chromatographic methods employed throughout the synthesis of the target 
compounds. The byproduct in question originates from the conversion of 10 to 
11, where freshly generated organolithium species using t-BuLi are added to 
aldehydes 10. Being that lithium-halogen exchange reactions are an equilibrium 
process based on the comparative stability between the exchanging species, 
these reactions will always generate an amount of the undesired “t-butyl adduct”, 
which was synthesized and subjected to the same bioassays as all other 
compounds to determine how the presence of this undesired byproduct affected 
the observed activities of the screened GC analogues. All intermediates were 
only carried forward if TLC analysis revealed the purified compound as a single 
spot by UV visualization and/or TLC staining. Although the synthetic GCs 
subjected to ex-vivo biological testing were not pure single molecules, the fact 
that these “impurities” were found in nearly all the compounds assayed should 
indicate that the observed activities for the compounds tested are directly related 
to the desired synthetic GC analogue.  
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2.3.3 Stereochemistry of non-steroidal glucocorticoids 
The synthetic scheme for the non-steroidal glucocorticoids in figure 20 includes 
enantiomeric and diastereomeric excess (ee, de) percentages listed for 
analogues 4 through 13. Chiral centers were introduced into the structure at the 
synthesis of analogues 4, 10, 11 and 13. The enantiomers/diastereomers where 
not separated due to the study being an initial screening for bioactivity. The 
insertion of the first chiral carbon at molecule 4 was an asymmetric 
intramolecular cyclization using the L-proline protocol to synthesize the Wieland-
Miescher ketone.112 The selectivity reported for the conversion to the Wieland-
Miescher ketone was 70% ee. The enantiomers were carried through the 
reaction steps until the addition of the second chiral carbon using a Wittig 
reaction to form molecule 10. The installment of the aldehyde was done similar to 
the reported synthetic step in the 2004 synthesis of the Merck scaffold.55 They 
reported a diastereomeric ratio of 8:1, which combined with the previous 
enantiomeric excess of 70% ee would produce a 2% ee and 52% de for molecule 
10. The final two carbon centers in the synthesis were installed in secondary 
alcohol 11 and the tertiary alcohol 13. Ali and coworkers reported only a single 
diastereomer was afforded in both steps. Therefore, the enantiomeric/ 
diastereomeric excess ratios of 2% and 50% were carried through molecule 13.  
2.3.4 Synthesis of steroidal glucocorticoids 
The total synthesis for the steroidal glucocorticoid scaffold analogues tested were 
prepared with a previously published synthesis on modifications to 
hydrocortisone with slight modifications.111 A total of 10 molecules were 
synthesized using 6 different synthetic glucocorticoids. A general procedure for 
the construction of the steroidal GC scaffold analogues is presented in figure 21. 
The commercially available synthetic glucocorticoid 1a-f was converted to the 
intermediate mesylate with the use of N,N-Diisopropylethylamine (DIPEA) in 
dichloromethane. The mesylated steroid was not purified and the crude product 
was reacted directly with 2-mercaptobenzothiazole to afford products 2a-f. For 
102 
 
the second derivatization of the synthetic steroids, 2a-d were subjected to a 
reaction with furoyl chloride under basic conditions to afford products 3a-d 
2.3.5 Purification of steroidal glucocorticoids 
The objective was to obtain a purity of >99% for this set of molecules moving 
forward to biological testing. The commercially available purchased synthetic 
glucocorticoids arrived with purity ranging from 95%-99%. All purification was 
done on normal phase column chromatography using silica gel as the stationary 
phase with various mobile phases being used. All crude products were dry 
loaded onto columns adhered to silica to limit the amount of line-broadening as 
the mobile phase was added. The initial conversion 1a to 2a was done in two 
steps with purification of the mesylate intermediate before conversion to the 
mercaptobenzothiazole derivative. The overall yield of the two steps was 80% in 
the first series of derivatives synthesized for the dexamethasone analogue, 2a. 
The yield forgoing the purification of the mesylate intermediate and subsequent 
reaction with the 2-mercaptobenzothiazole yielded 70% conversion. It was 
determined that the rest of the derivatives would forgo the initial purification of the 
intermediate and save time and money. The purification of the mesylate required 
large amounts of silica and solvent and upon purification the compound would 
need to be dried under vacuum before it can be used in the reaction with 2-
mercaptobenzothiazole. The purification of 2a-f was aided through TLC of the 
reaction while it was being actively stirred. The starting material will be 
completely consumed given the correct amount of time and molar equivalency 
added through both the methylation and mercaptobenzothiazole derivatization. 
The reactions were monitored and only stopped when the starting material was 
not visible on a TLC plate using a potassium permanganate (KMnO4) stain. The 
KMnO4 stain proved to be more sensitive towards this particular set of molecules 
over simply observing the compound under the UV light. 2a-f were purified using 





Figure 21: Synthetic route for the synthesis of the steroidal glucocorticoid scaffold analogues
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Each product was found to be a white solid upon drying off column solvent. 
Products 3a-d proved a challenging purification. The separation was difficult due 
to the byproducts and remaining starting material having very similar retention 
factors. The previous literature mentioned the reaction should be halted upon 
complete consumption of the starting material. Although in the synthesis of 3a-d, 
starting material was found in each of their respective crude oils after reaction 
completion. Several trouble shooting steps were undertaken, and reactions were 
done increasing the heat as well as time stirring. Neither option proved 
worthwhile as trace amounts of starting material remained after analysis by 1H-
NMR. In fact, adding heat caused the addition of a second furoyl group to the 
molecule. The purification following literature on similar molecules was done 
using a silica stationary phase with a mobile phase consisting of 1% 
methanol/chloroform solution. This was sufficient column for most of the 
byproducts in the crude oil except for the starting material. To separate 3a-d from 
2a-d a non-protic polar solvent was needed. For this, a gradient mobile phase 
was used starting at a concentration of 5% EtOAc/hexanes and eluting at 25% 
EtOAc/hexanes. Each of the compounds had a purity >97% upon analysis by 1H-
NMR 
2.4 Molecular Modeling 
To better understand the results from the data obtained from bioassays, ligand-
receptor interactions were modeled between the synthesized non-steroidal GC 
molecules subjected to ex-vivo testing and the human glucocorticoid receptor 
(PDB ID: 5NFP)113. Ligand models were prepared in Chem3D (PerkinElmer) to 
generate a structure in the lowest-energy conformation to be used in the docking 
experiment. Docking was performed between the rigid 5NFP GR and the flexible 
ligands generated from Chem3D using AutoDock Vina (The Scripps Research 
Institute)114, and the resulting docking conformations were viewed in 3D with 
PyMol (Schrödinger).115 2D ligand-residue interaction figures were generated 
with LigPlot+ (European Molecular Biology Laboratory)116. 2D and 3D 
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representations of the modeled interactions as well as calculated binding 
affinities (AutoDock Vina) can be found in the supporting information document 
(section 7). Ligand-residue interactions obtained from analysis using LigPlot+ 
were tabulated and further processed in R to create an interaction map. (Figure 
22) 
2.5 Materials and Methods 
2.5.1 Non-steroidal glucocorticoid synthetic procedure 
Procedures for obtaining compound 6 were followed from a previously reported 
synthesis of N-arylpyrazolo[3,2-c]-based GC derivatives. The same general 
procedure can be followed for obtaining both tolyl- and anisolyl- (R1 = 1(4-
methylphenyl); 1-(4-methoxyphenyl)) GC analogue series starting from 
compound 6, the point of synthetic originality for this study. Synthetic procedures, 
chromatographic methods, and characterization data for intermediates and 
previously reported GC analogues will not be shown (namely the fluorophenyl 
series of GC analogues) except for GC analogues which were subjected to 
biological testing. 
General procedure for GC headgroup installation - compound series 7: To a 
solution of 6 (5.0 g, 20 mmol) in glacial acetic acid (50 mL) was added the 
appropriate phenylhydrazine HCl salt (23 mmol) and sodium acetate (1.88 g, 23 
mmol) and allowed to stir at room temperature for 2 h. The reaction mixture was 
then slowly and carefully poured into a cold (0-5 ˚C) and actively stirred solution 
of saturated NaHCO3. The neutralized solution was then extracted with EtOAc 
(5x100 mL), washed with brine, dried with anhydrous MgSO4, filtered, and 
concentrated in vacuo. Purification of the crude product was accomplished using 
flash chromatography (20% EtOAc/hexanes) to give a viscous orange oil.  
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydrospiro-[benzo[f]indazole-5,2'-
[1,3]dioxolane] (7b): From 6 using p-tolylphenylhydrazine HCl. Yield = 44%. 
TLC Rf = 0.28 (30% EtOAc/hexanes). 




Figure 22: Ligand-residue interaction map 
(left) displaying hydrophillic (pink) and hydrophobic (blue) interactions from Autodock Vina™ molecular docking 
simulations. The top binding conformation of compound 11aa is shown in the 5nfp binding pocket (right). Ligand 
shown with a green carbon skeleton while the residues are shown with a grey carbon skeleton. Heteroatoms are 
displayed in a typical fashion – N (blue); O (red); S (yellow); Hydrogen bond (cyan
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1.65-1.83 (m, 4H), 2.28 (dt, 2H), 2.4 (s, 3H), 2.51 (d, 1H), 3.16 (d, 1H), 3.99-4.08 
(m, 4H), 6.23 (s, 1H), 7.24-7.26 (d, 2H), 7.35-7.37 (d, 2H), 7.43 (s, 1H). 
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-
hexahydrospiro[benzo[f]indazole-5,2'-[1,3]dioxolane] (7c): From 6 using p-
methoxyphenylhydrazine HCl. Yield = 38%. TLC Rf = 0.27 (50% 
EtOAc/hexanes). 1H-NMR (CDCl3, 500 MHz) δ 1.22 (s, 3H), 1.68-1.83 (m, 3H), 
2.30-2.31 (d, 1H), 2.51-2.54 (d, 2H), 3.15-3.18 (d, 2H), 3.85 (s, 3H), 4.01-4.13 
(m, 4H), 6.17 (s, 1H), 6.97-7.41 (m, 5H). 
Acetal deprotection for preparation of ketone 8: To a solution of 7 (5.9 mmol) 
in THF (50 mL) was added 6 M HCl (3.9 mL, 23.6 mmol) and subjected to reflux 
for 3.5 h. The reaction mixture was then neutralized by the slow addition of 
saturated NaHCO3 and extracted with ethyl acetate (4x100 mL). The pooled 
organic layer was washed with brine, dried with anhydrous MgSO4, and 
concentrated in vacuo. Purification of the crude product was accomplished using 
flash chromatography to give a dull orange solid.  
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8b): 
From 7b. Flash column mobile phase - 15% EtOAc/hexanes. Yield = 72%. TLC 
Rf = 0.34 (30% EtOAc/hexanes). 
1H-NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.62-
1.71 (m, 1H), 2.06-2.11 (m, 1H), 2.40 (s, 3H), 2.51-2.57 (m, 2H), 2.60-2.67 (m, 
2H), 2.90 (s, 2H), 6.33 (s, 1H), 7.26-7.28 (d, 2H), 7.35-7.38 (d, 2H), 7.48 (s, 1H). 
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-
5-one (8c): From 7c. Flash column mobile phase - 20% EtOAc/hexanes. Yield = 
77%. TLC Rf = 0.28 (40% EtOAc/hexanes). 
1H-NMR (CDCl3, 500 MHz) δ 1.24 (s, 
3H), 1.60-1.73 (m, 1H), 2.04-2.11 (m, 1H), 2.49-2.69 (m, 4H), 2.93 (d, 2H), 3.85 
(s, 3H), 6.26 (s, 1H), 6.95-7.47 (m, 5H). 
General Procedure for the synthesis of aldehydes 10: A commercially 
available solution of potassium bis(trimethylsilyl)amide in toluene (0.5 M, 33.12 
mL, 16.5 mmol) was added dropwise with a syringe to an actively stirred 
suspension of methoxymethyltriphenylphosphonium chloride (6.81 g, 19.8 mmol) 
in THF (65 mL) cooled to -40 °C. The solution was warmed to 0 °C and stirred at 
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that temperature for 15 min and a color change from pale yellow to dark red was 
observed. A solution of the appropriate ketone precursor 8 (6.6 mmol) in THF (16 
mL) was transferred dropwise via canula to the chilled ylide. After stirring for 24 
h, the reaction was quenched by the addition of 1:1 THF/MeOH (16 mL), diluted 
with three reaction volumes of EtOAc, washed with water and brine, dried over 
MgSO4, filtered, concentrated in vacuo and subjected to flash chromatography 
(15% EtOAc/hexanes). Fractions containing enol either 9 were collected, 
concentrated in a round bottom flask, and dissolved in THF. To the prepared 
solution of 9 in THF was added 4 M HCl and could stir at room temperature for 
36 h. The reaction mixture was afterward diluted with EtOAc - washed with water, 
saturated NaHCO3, and brine. The organic layer was dried over MgSO4, filtered, 
and concentrated in vacuo to give crude aldehyde 10 as a beige solid. 
Purification of the crude product was accomplished using flash chromatography 
(15% EtOAc/hexanes). 
4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-
carbaldehyde (10b): Yield = 40.0 %. TLC Rf = 0.31 (25% EtOAc/hexanes). 
1H-
NMR (CDCl3, 300 MHz) δ 1.12 (s, 3H), 1.30-1.40 (m, 2H) 1.70-1.78 (m, 2H), 
1.90-1.96 (m, 1H), 2.32-2.44 (m, 2H), 2.40 (s, 3H), 2.91 (d, 1H), 3.10 (d, 1H), 
6.21 (s, 1H), 7.26-7.28 (d, 2H), 7.35-7.37 (d, 2H), 7.44 (s, 1H), 9.90 (s, 1H) 
1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-
5-carbaldehyde (10c): Yield = 45.0 %. TLC Rf = 0.28 (25% EtOAc/hexanes). 
1H-
NMR (CDCl3, 500 MHz) δ 1.11 (s, 3H), 1.39-1.43 (m, 1H), 1.72-1.75 (m, 1H), 
1.90-1.96 (m, 2H), 2.33-2.44 (m, 3H), 2.89-2.92 (d, 1H), 3.08-3.11 (d, 1H), 3.85-
3.86 (s, 3H), 6.15 (s, 1H), 6.95-7.42 (m, 5H), 9.90 (s, 1H). 
General Procedure for R2 = methyl 2˚OH analogues: A commercially available 
solution of 1.6 M MeLi in Et2O (312 µL, 0.5 mmol) was transferred via syringe to 
a round bottom flask containing diethyl ether (5 mL) and cooled to -78 °C. A 
solution of the appropriate aldehyde 10 (0.05 mmol) in THF (5 mL) was added 
dropwise via canula, and the reaction was stirred at -78 °C for 45 min. The 
reaction was quenched with isopropyl alcohol (IPA), poured into a separatory 
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funnel containing saturated NH4Cl, and extracted three times with EtOAc. The 
organic phase was washed with once each with water and brine, dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the crude 
product was accomplished using flash chromatography (15% EtOAc/hexanes) to 
give a white solid.  
1-(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)ethan-1-ol (11ba): From 10b using MeLi (1.6 M solution in Et2O). Yield = 50%. 
Flash column mobile phase – 30-40% EtOAc/hexanes. TLC Rf = 0.16 (30% 
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H27N2O, 
323.21179; found 323.21001. 1H-NMR (CDCl3, 500 MHz): δ 1.13 (s, 3H), 1.23-
1.29 (m, 3H), 1.34-1.45 (m, 2H), 1.56-1.62 (m, 2H), 1.72-1.78 (m, 1H), 1.90-1.94 
(m, 1H), 2.27-2.30 (m, 1H), 2.32-2.37 (m, 4H) 2.47-2.50 (d, 1H), 2.97-3.00 (d, 
1H), 6.14 (s, 1H), 7.23-7.26 (d, 2H), 7.34-7.36 (d, 2H), 7.40 (s, 1H) 
1-(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)ethan-1-ol (11ca): From 10c using MeLi (1.6 M solution in 
Et2O). Yield = 58%. Flash column mobile phase – 30% EtOAc/hexanes. TLC Rf = 
0.11 (25% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for 
C21H27N2O2, 339.20670; found 339.20344. 
1H-NMR (CDCl3, 500 MHz): δ 1.13 (s, 
3H), 1.23-1.29 (m, 4H), 1.34-1.45 (m, 3H), 1.74-1.78 (d, 1H),1.88-1.95 (d, 1H), 
2.28-2.31 (d, 1H), 2.35-2.39 (m, 1H), 2.47-2.51 (d, 1H), 2.98-3.01 (d, 1H), 3.84-
3.87 (s, 3H), 6.10 (s, 1H), 6.96-7.40 (m, 5H). 
General Procedure for R2 = phenyl 2˚OH analogues: 
A commercially available solution of 1.9 M PhLi in di-n-butyl ether (3.42 mL, 6.5 
mmol) was transferred to a round bottom flask containing a small portion of dry 
Et2O and was cooled to -78 °C. A solution of 10 (0.65 mmol) in THF (2 mL) was 
added dropwise via canula, and the reaction was stirred at -78 °C for 45 min. The 
reaction was quenched with IPA, poured into a separatory funnel containing 
saturated NH4Cl, and extracted three times with EtOAc. The organic phase was 
washed with once each with water and brine, dried over anhydrous MgSO4, 
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filtered, and concentrated in vacuo. Purification of the crude product was 
accomplished using flash chromatography. 
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(phenyl)methanol (11bb): From 10b using PhLi (1.9 M solution in di-n-butyl 
ether). Flash column mobile phase – 15% EtOAc/hexanes, to give a white solid. 
Yield = 28%. TLC Rf = 0.20 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C26H29N2O, 385.22744; found 385.22612. 
1H-NMR (CDCl3, 500 
MHz): δ 1.26 (s, 3H), 1.60-1.81 (m, 5H), 2.23-2.28 (d, 1H), 2.36-2.43 (m, 4H), 
2.74-2.77 (d, 1H) 3.15-3.18 (d, 1H), 5.17 (s, 1H), 6.15 (s, 1H), 7.23-7.27 (d, 3H), 
7.34-7.38 (m, 6H), 7.41 (s, 1H). 
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-
5-yl)(phenyl)methanol (11cb): From 10c using PhLi (1.9 M solution in di-n-butyl 
ether). Flash column mobile phase – 20% EtOAc/hexanes, to give a beige solid. 
Yield = 73 %. TLC Rf = 0.11 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C26H29N2O2, 401.22235; found 401.21952. 
1H-NMR (CDCl3, 
500 MHz): δ 1.27 (s, 3H), 1.56-1.81 (m, 6H), 2.24-2.27 (d, 1H), 2.36-2.44 (m, 
1H), 2.75-2.78 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 5.20 (s, 1H), 6.11 (s, 1H), 
6.96-7.44 (m, 9H). 
General Procedure for R2 = 4-fluorophenyl 2˚OH analogues: A commercially 
available solution of 2.0 M 4-fluorophenylmagnesium bromide in diethyl ether 
was transferred to a round bottom flask and cooled to -78 °C. A solution of 8 R1 
= Me in THF was added dropwise via canula, and the reaction was stirred at -78 
°C for 45 min. The reaction was quenched with IPA, poured into a separatory 
funnel containing saturated NH4Cl, and extracted three times with EtOAc. The 
organic phase was washed with once each with water and brine, dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the crude 
product was accomplished using flash chromatography to give a white solid. 
(4-fluorophenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11bc): From 10b using 4-
fluorophenylmagnesium bromide (2.0 M in Et2O). Flash column mobile phase – 
111 
 
10% EtOAc/hexanes. Yield = 11.5 %. TLC Rf = 0.24 (25% EtOAc/hexanes). 
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C26H28FN2O, 403.21802; found 
403.21649. 1H-NMR (CDCl3, 500 MHz): δ 1.26 (s, 3H), 1.50-1.61 (m, 3H), 1.67-
1.71 (m, 2H), 1.79-1.82 (d, 1H), 2.25-2.28 (d, 1H), 2.39 (s, 3H), 2.74-2.77 (d, 1H), 
3.16-3.20 (d, 1H), 5.19 (s, 1H), 6.16 (s, 1H), 7.02-7.46 (m, 9). 
(4-fluorophenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11cc): From 10c using 4-
fluorophenylmagnesiumbromide (2.0M in Et2O). Flash column mobile phase - 
15% EtOAc/hexanes. Yield = 69%. TLC Rf = 0.26 (30% EtOAc/hexanes). HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C26H28FN2O2, 419.21293; found 419.20660. 
1H-NMR (CDCl3, 500 MHz): δ 1.26 (s, 3H), 1.56-1.58 (m, 2H), 1.66-1.70 (m, 2H), 
1.79-1.82 (m, 1H), 2.25-2.28 (m, 1H), 2.37-2.40 (m, 1H), 2.73-2.76 (d, 1H), 3.17-
3.20 (d, 1H), 3.85 (s, 3H), 5.20 (d, 1H), 6.11 (s, 1H), 6.96-7.06 (m, 4H), 7.30-7.44 
(m, 5H). 
General Procedure for R2 = 2,3-difluoroanisolyl 2˚OH analogues: A solution 
of 5-Bromo-2,3-difluoroanisole (4.6 mmol) in THF (10 mL) was cooled to -78 °C, 
to which a commercially available solution of 1.9 M t-BuLi in pentanes (4.6 mmol, 
2.9 mL) was added dropwise via syringe. The reaction was stirred for 20 min at -
78 °C, raised to 0 °C for 5-10 min until the solution transitioned from pale yellow 
to dark yellow-green, and then was immediately cooled back to -78 °C for 5 min. 
A solution of 10 (0.46 mmol) in THF (2 mL) was added dropwise via canula, and 
the reaction was stirred at -78 °C for 1 h. The reaction was quenched with IPA, 
poured into a separatory funnel containing saturated NH4Cl, and extracted three 
times with EtOAc. The organic phase was washed with water and brine, dried 
over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the 
crude product was accomplished using flash chromatography to give a white 
solid. 
(3,4-difluoro-5-methoxyphenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)methanol (11ad): From 10a using 
commercially available 5-bromo-2,3-difluoroanisole. Flash column mobile phase 
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– 30% EtOAc/hexanes. Yield = 61.9 %. TLC Rf = 0.26 (25% EtOAc/hexanes). 
1H-
NMR (CDCl3, 300 MHz) δ 1.26 (s, 3H), 1.54-1.57 (m, 1H), 1.64-1.72 (m, 1H), 
1.82-1.86 (m, 2H), 2,28-2.46 (m, 3H), 2.72-2.77 (d, 1H), 3.17-3.22 (d, 1H), 3.92 
(s, 3H), 5.12 (s, 1H), 6.12 (s, 1H), 6.72-6.80 (m, 2H), 7.15-7.21 (m, 2H), 7.45-
7.54 (m, 3H). 
(3,4-difluoro-5-methoxyphenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-
1H-benzo[f]indazol-5-yl)methanol (11bd): From 10b using commercially 
available 5-bromo-2,3-difluoroanisole. Flash column mobile phase - 10% 
EtOAc/hexanes. Yield = 76.7 %. TLC Rf = 0.22 (25% EtOAc/hexanes). HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O2, 451.21916; found 
451.21790. 1H-NMR (CDCl3, 500 MHz) δ 1.25 (m, 3H), 1.37-1.50 (m, 2H), 1.54-
1.65 (m, 2H), 1.76-1.79 (d, 1H), 2.04 (s, 3H), 2.26-2.29 (d, 1H), 2.72-2.75 (d, 1H), 
3.14-3.17 (d, 1H), 3.88 (s, 3H), 5.10 (s, 1H), 6.16 (s, 1H), 6.72-6.78 (m, 2H), 
7.24-7.46 (m, 6H). 
(3,4-difluoro-5-methoxyphenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)methanol (11cd): From 10c using 
commercially available 5-bromo-2,3-difluoroanisole. Flash column mobile phase - 
15% EtOAc/hexanes. Yield = 71.4 %. TLC Rf = 0.16 (30% EtOAc/hexanes). 
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O3, 467.21408; found 
467.21488. 1H-NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.52-1.56 (m, 2H), 1.66-
1.69 (m, 2H), 1.80-1.84 (m, 2H), 2.26-2.29 (m, 1H), 2.73-2.76 (d, 1H), 3.15-3.18 
(d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 5.12 (s, 1H), 6.11 (s, 1H), 6.72-6.79 (m, 2H), 
6.96-6.99 (m, 2H), 7.37-7.44 (m, 3H). 
General Procedure for R2 = thiophenyl 2˚OH analogues: A solution of 3-
bromothiophene (0.6 mL, 6.4 mmol) in THF (10 mL) was cooled to -78 °C, to 
which a commercially available solution of 1.9 M t-BuLi in pentanes (6.8 mL, 12.8 
mmol) was added dropwise via syringe. After the reaction stirred for 30 min at -
78 °C, a solution of 10 (6.4 mmol) in THF (2 mL) was added dropwise via canula, 
and the reaction was allowed to gradually warm to room temperature over the 
course of 1.5 h. After returning the reaction to -78 °C, the reaction was quenched 
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with IPA, poured into a separatory funnel containing saturated NH4Cl, and 
extracted three times with EtOAc. The organic phase was washed with water and 
brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Purification of the crude product was accomplished using flash chromatography 
(10% EtOAc/hexanes) to give a white solid. 
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-3-yl)methanol (11ae): From 10a using commercially available 3-
bromothiophene. Flash column mobile phase – 10% EtOAc/hexanes. Yield = 
35.8%. TLC Rf = 0.26 (25% EtOAc/hexanes). 
1H-NMR (CDCl3, 500 MHz) δ 1.24 
(s, 3H), 1.65-1.93 (m, 5H), 2.27-2.48 (m, 2H), 2.67-2.72 (d, 1H), 3.08-3.15 (d, 
1H), 5.24 (s, 1H), 6.12 (s, 1H), 6.94-6.99 (m, 1H), 7.12-7.24 (m, 3H), 7.30-7.33 
(m, 1H), 7.43-7.48 (m, 3H). 
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-3-yl)methanol (11be): From 10b using commercially available 3-
bromothiophene. Flash column mobile phase – 10% EtOAc/hexanes. Yield = 
35.8%. TLC Rf = 0.26 (25% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]
+ 
Calcd for C24H27N2OS, 391.18386; found 391.13976. 
1H-NMR (CDCl3, 500 MHz) 
δ 1.23 (s, 3H), 1.62-1.91 (m, 6H), 2.26-2.31 (m, 1H), 2.40 (s, 3H), 2.67-2.72 (m, 
1H), 3.06-3.14 (m, 1H), 5.39 (s, 1H), 6.16 (s, 1H), 6.95-7.43 (m, 8H). 
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-
5-yl)(thiophen-3-yl)methanol (11ce): From 10c using commercially available 3-
bromothiophene. Flash column mobile phase – 15% EtOAc/hexanes. Yield = 
79.5%. TLC Rf = 0.17 (30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]
+ 
Calcd for C24H27N2O2S, 407.1787; found 407.1720. 
1H-NMR (CDCl3, 500 MHz) δ 
1.26 (m, 4H), 1.62-1.72 (m, 2H), 1.77-1.85 (m, 2H), 2.27-2.41 (m, 2H), 2.69-2.72 
(d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 5.25 (s, 1H), 6.12 (s, 1H), 6.96-7.40 (m, 
8H). 
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-
5-yl)-3-hydroxypropanenitrile (11af): A commercially available solution of 1.7 M 
t-BuLi in pentanes (0.9 mL, 1.53 mmol) was transferred to a round bottom flask 
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containing THF (2 mL) and cooled to -78 °C. A solution of ACN (80 µL) in THF (2 
mL) was added dropwise at -78 °C. Following addition, a solution of 10a (400 
mg, 1.3 mmol) in THF (2 mL) was added dropwise via canula, and the reaction 
was stirred at -78 °C for 1 h. The reaction was quenched with saturated NH4Cl, 
acidified to a pH of 7 via dropwise addition of 0.5 M HCl, and extracted three 
times with diethyl ether. The organic phase was washed with water and brine, 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of 
the crude product was accomplished using flash chromatography (25% 
EtOAc/hexanes) to give a white solid. Yield = 45.5%. TLC Rf = 0.14 (25% 
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H23FN3O, 
352.18197; found 352.18293. 1H-NMR (CDCl3, 500 MHz) δ 1.04-1.13 (s, 3H), 
1.25-1.46 (m, 2H), 1.61-1.71 (m, 2H), 1.78-1.97 (m, 2H), 2.30-2.42 (m, 2H), 2.47-
2.72 (m, 3H), 2.93-3.21 (d, 1H), 4.16-4.40 (m, 1H), 6.12 (s, 1H), 7.14-7.44 (m, 
5H). 
General method for the synthesis of intermediate 12: A solution of the 
appropriate 2˚-OH precursor (11) in dichloromethane was transferred dropwise 
via canula to a suspension of pyridinium chlorochromate (1.5 molar equivalents 
to compound being oxidized) and freshly activated 4 Å molecular sieves (an 
equivalent weight to compound being oxidized) in dichloromethane. The reaction 
was stirred at room temperature until complete conversion was observed by TLC 
analysis (reaction times varied from 1-7 h). Upon complete conversion, the 
reaction mixture was immediately loaded onto a prepared florisil column (packed 
DCM slurry) and subjected to purification via flash chromatography (100% DCM 
flush) to give ketone 12 in sufficient purity to move forward with the synthesis.  
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-
5-yl)-3-hydroxybutanenitrile (12af): White solid obtained from 11af with PCC 
as the oxidizing agent. Yield = 16%. TLC Rf = 0.11 (30% EtOAc/hexanes). HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C21H21FN3O, 350.16632; found 350.16529. 
1H-NMR (CDCl3, 500 MHz) δ 1.20 (s, 3H), 1.45-1.49 (m, 2H), 1.82-1.87 (t, 2H), 
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1.93-1.97 (d, 1H), 2.32-2.44 (m, 3H), 2.74-2.77 (d, 1H), 2.82-2.88 (m, 2H), 3.53-
3.61 (s, 2H), 6.15 (s, 1H), 7.14-7.44 (m, 5H). 
General method for the synthesis of compound 13 analogues: The 
appropriate ketone precursor (12) was dissolved in diethyl ether and cooled to -
40 °C, and a commercially available solution of MeLi (1.9 M, 10 equivalents to 
ketone starting material) was added dropwise via syringe. The reaction was 
stirred under argon at -40° for 45 min. The reaction was quenched with IPA (10 
equivalents to MeLi added), poured into a separatory funnel containing saturated 
NH4Cl, and extracted with EtOAc. The organic phase was washed with water and 
brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Purification was accomplished using flash chromatography (see each entry for 
respective column conditions) 
2-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13ba): From appropriate ketone 12 using commercially available 
MeLi (1.9 M in Et2O) to give a white solid in 55% yield. Flash column mobile 
phase - 20% EtOAc/hexanes. TLC Rf = 0.17 (25% EtOAc/hexanes). HRMS (ESI-
RTOF) m/z: [M+H]+ Calcd for C22H29N2O, 337.2274; found 337.2200. 
1H-NMR 
(CDCl3, 500 MHz) δ 1.19 (s, 3H), 1.33-1.37 (s, 8H), 1.38-1.39 (d, 1H), 1.66-1.69 
(d, 1H), 1.77-1.80 (dt, 1H), 1.84-1.87 (dt, 1H), 2.31 (m, 1H), 2.39 (s, 3H), 2.73-
2.76 (d, 1H), 3.53-3.57 (d, 1H), 6.16 (s, 1H) 7.24-7.25 (d, 2H), 7.35-7.38 (d, 2H), 
7.40 (s, 1H). 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)-1-phenylethan-1-ol (13bb): From appropriate ketone 12 using commercially 
available MeLi (1.9 M in Et2O) to give a white solid in 82% yield. Flash column 
mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.27 (30% EtOAc/hexanes). 
HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C27H31N2O, 399.2430; found 399.2368. 
); 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.62-1.66 (m, 2H), 1.68 (s, 3H), 
1.74-1.79 (m, 2H), 2.04-2.07 (d, 1H), 2.24-2.28 (d, 1H), 2.33-2.40 (m, 4H), 2.60-
2.63 (d, 1H), 3.10-3.13 (d, 1H), 6.14 (s, 1H), 7.23-7.29 (m, 4H), 7.33-7.36 (m, 




benzo[f]indazol-5-yl)ethan-1-ol (13bc): From appropriate ketone 12 using 
commercially available MeLi (1.9 M in Et2O) to give a white solid in 80% yield. 
Flash column mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.25 (30% 
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H30FN2O, 
417.23367; found 417.23232. 1H-NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.60-
1.63 (m, 3H), 1.66 (s, 3H), 1.75-1.79 (d, 1H), 1.99-2.02 (d, 1H), 2.24-2.27 (d, 1H), 
2.39 (s, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 5.30 (s, 1H), 6.14 (s, 1H), 7.01-
7.48 (m, 9H). 
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13bd): From appropriate 
ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid 
in 94% yield. Flash column mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.19 
(30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C28H31F2N2O2, 
465.2348; found 465.2283. 1H-NMR (CDCl3, 500 MHz) δ 1.22-1.35 (m, 6H), 1.58-
1.62 (m, 4H), 1.79-1.83 (d, 1H), 1.96-1.99 (d, 1H), 2.25-2.28 (d, 1H), 2.34-2.44 
(s, 3H), 2.57-2.61 (d, 1H), 3.05-3.08 (d, 1H), 3.91-3.96 (s, 3H), 6.15 (s, 1H), 6.87-
6.92 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (s, 1H). 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)-1-(thiophen-2-yl)ethan-1-ol (13be): From appropriate ketone 12 using 
commercially available MeLi (1.9 M in Et2O) to give a white solid in 76% yield. 
Flash column mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.28 (25% 
EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C25H29N2OS, 
405.1995; found 405.1899. 1H-NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.40-1.41 
(d, 1H), 1.57-1.59 (d, 1H), 1.65 (s, 3H), 1.69-1.70 (d, 2H), 1.76-1.78 (d, 1H), 
2.03-2.06 (d, 1H), 2.26-2.28 (d, 1H), 2.39 (s, 3H), 2.66-2.69 (d, 1H), 3.22-3.25 (d, 
1H), 6.15 (s, 1H), 7.12-7.37 (m, 8H). 
2-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)propan-2-ol (13ca): From appropriate ketone 12 using 
commercially available MeLi (1.9 M in Et2O) to give a white solid in 58% yield. 
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Flash column mobile phase - 25% EtOAc/hexanes. TLC Rf = 0.08 (30% 
EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C22H29N2O2, 
353.2223; found 353.2184. 1H-NMR (CDCl3, 500 MHz) δ 1.19 (s, 3H) 1.30-1.38 
(d, 6H), 1.48-1.55 (m, 1H), 1.66-1.69 (d, 1H), 1.76-1.87 (dd, 2H), 2.27-2.37 (m, 
3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 3.85 (s, 3H), 6.11 (s, 1H) 6.95-7.41 (m, 
5H). 
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)-1-phenylethan-1-ol (13cb):  From appropriate ketone 12 
using commercially available MeLi (1.9 M in Et2O) to give a beige solid in 100% 
yield. Flash column mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.20 (30% 
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H31N2O2, 
415.23800; found 415.23680. 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.55-
1.63 (m, 3H), 1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26 (m, 
1H), 2.33-2.38 (m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H), 6.08 (s, 
1H), 6.95-7.51 (m, 10H). 
1-(4-fluorophenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cc): From appropriate 
ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid 
in 49% yield. Flash column mobile phase - 20% EtOAc/hexanes. TLC Rf = 0.28 
(30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for 
C27H30FN2O2, 433.22858; found 433.22897. 
1H-NMR (CDCl3, 300 MHz) δ 1.25 
(s, 3H), 1.53-1.62 (m, 2H), 1.67 (s, 3H), 1.73-1.78 (m, 1H), 1.99-2.02 (d, 1H), 
2.24-2.36 (m, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 6.09 (s, 1H), 
6.95-7.49 (m, 9H). 
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-
4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cd): From 
appropriate ketone 12 using commercially available MeLi (1.9 M in Et2O) to give 
a white solid in 65% yield. Flash column mobile phase - 15% EtOAc/hexanes. 
TLC Rf = 0.13 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]
+ Calcd 
for C27H30FN2O2, 433.22858; found 433.22897. 
1H-NMR (CDCl3, 500 MHz) δ 
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1.26 (s, 3H), 1.60-1.67 (m, 6H) 1.79-1.82(d, 1H), 1.96-1.99 (d, 1H), 2.24-2.39 (m, 
2H), 2.57-2.60 (d, 1H), 3.05-3.08 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 6.10 (s, 1H), 
6.87-7.01 (m, 4H), 7.32-7.45 (m, 3H). 
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)-1-(thiophen-2-yl)ethan-1-ol (13ce): From appropriate 
ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid 
in 48% yield. Flash column mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.16 
(30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for 
C25H29N2O2S, 421.1944; found 421.1907. 1H-NMR (CDCl3, 500 MHz) δ1.25 
(s, 3H), 1.59-1.65 (m, 2H), 1.68 (s, 3H), 1.73-1.78 (m, 2H), 2.03-2.06 (d, 1H), 
2.25-2.36 (m, 2H), 2.65-2.69 (d, 1H), 3.22-3.25 (d, 1H), 3.84 (s, 3H), 6.10 (s, 1H), 
6.94-7.40 (m, 8H) 
2.5.2 Steroidal glucocorticoid synthetic procedure 
The procedure used for the synthesis of all mercaptocoids was previously 
reported with slight modifications of known methods.56 All reactions were done 
under inert atmosphere using dry solvents unless otherwise stated. All chemicals 
and solvents were purchased through VWR or Fisher Scientific and were reagent 
grade. NMRs were taken on a Varian VNMRS 500 MHz.  
General Procedure for R1 instillation: The appropriate steroid was stirred into 
dichloromethane and the mixture was cooled to 0 °C. 7.5 molar equivalents of 
diisopropylethylamine (DIPEA) was added to cold solution followed directly by 
1.5 molar equivalents of mesylchloride (MsCl). The reaction was slowly warmed 
to room temperature and stirred for 15 hours or until completion monitored 
through TLC. Once the starting material was not visible on TLC, the reaction was 
concentrated in vacuo. The resulting oil was then redissolved in dichloromethane 
and washed with saturated bicarbonate. The water layer was then extracted with 
dichloromethane. The organic layers were then combined and washed with brine 
in triplicate. The organic layers were dried with MgSO4, filtered, and concentrated 
to give a light brown crystalline solid as the mesylate of the steroid. The 
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intermediate was carried crude through the next reaction.  The steroid mesylate 
was then dissolved in reagent grade acetone. 10 molar equivalents of potassium 
carbonate were then added to the solution followed directly by 2 molar 
equivalents of 2-mercaptobenzothiazole and the resulting mixture was refluxed 
for 1 hour. One completion of the reaction monitored through TLC, the mixture 
was filtered through a pad of silica and the filtrate was concentrated in vacuo to 
give a white solid. The product was then purified by column chromatography 




dodecahydro-3H-cyclopenta[a]phenanthren-3-one (2a): From 
dexamethasone using 2-mercaptobenzothiazole to give a white solid in 70% 
yield. Flash column mobile phase 40% EtOAc/hexanes TLC Rf = 0.20 (25% 
EtOAc/hexanes 1H-NMR (CDCl3, 500 MHz) δ 0.91 (d, 3H), 1.03 (s, 3H), 1.24-
1.32 (m, 2H), 1.47 (dd, 1H), 1.56 (s, 3H), 1.67 (m, 3H), 1.84-1.89 (dt, 1H), 2.33-
2.45 (m, 3H), 2.59-2.66 (m, 1H), 2.77-2.81 (dt, 1H), 3.14-3.16 (d, 1H), 3.12-3.18 
(m, 1H), 4.39-4.45 (m, 1H), 5.03-5.07 (d, 1H), 6.02 (s, 1H), 6.13 (s, 1H), 6.33-
6.35 (dd, 1H), 7.19-7.23 (d, 1H), 7.29-7.31 (ddd, 1H), 7.39-7.41 (ddd, 1H), 7.70-
7.78 (dd, 2H) 13C-NMR (CDCl3, 500 MHz) δ 15.59, 17.33, 23.01, 23.06, 27.28, 
31.08, 32.48, 34.18, 34.33, 37.96, 47.36, 48.13, 48.31, 72.47, 92.14, 120.78, 
121.24, 124.81, 125.14, 125.14, 129.03, 134.91, 151.81, 167.18, 186.51, 206.59 
(9R,10S,11S,13S,16S,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-9-fluoro-
11,17-dihydroxy-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-
dodecahydro-3H-cyclopenta[a]phenanthren-3-one (2b): From 
Betamethasone using 2-mercaptobenzothiazole to give a white solid in 68% 
yield. Flash column mobile phase 40% EtOAc/hexanes TLC Rf = 0.24 (25% 
EtOAc/hexanes 1H-NMR (CDCl3, 500 MHz) δ 0.96 (s, 3H), 1.13-1.23 (m, 3H), 
1.39-1.41 (m, 3H), 1.45 (s, 3H), 1.60-1.64 (m, 2H), 1.81-1.95 (m, 3H), 2.00-2.09 
(m, 2H) 2.15-2.20 (m, 1H) 2.20-2.30 (m, 1H), 2.23-2.40 (m, 2H), 2.43-2.53 (m, 
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2H), 2.69-2.80 (m, 1H), 3.35-3.45 (d, 1H), 4.45-4.55 (m, 1H), 5.06-5.14 (d,1H), 
5.70 (s, 1H) 7.30-7.36 (t, 1H), 7.39-7.44 (t, 1H), 7.72-7.76 (d, 1H), 7.80-7.84 (d, 
1H) 13C-NMR (CDCl3, 500 MHz) δ 14.18, 17.48, 19.97, 23.01, 27.56, 31.12, 
33.70, 35.12, 38.72, 39.20, 43.39, 46.81, 47.69, 48.29, 52.08, 60.40, 68.50, 
72.17, 72.47, 90.28, 91.08, 120.43, 121.33, 122.31, 124.97, 126.68, 129.75, 
152.40, 166.47, 186.69, 206.34 
(10R,11S,13S,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-11,17-dihydroxy-
10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-
cyclopenta[a]phenanthren-3-one (2c): From prednisolone using 2-
mercaptobenzothiazole to give a white solid in 74% yield. Flash column mobile 
phase 40% EtOAc/hexanes TLC Rf = 0.22 (25% EtOAc/hexanes 
1H NMR (500 
MHz, Chloroform-d) δ 7.75 (s, 1H), 7.70 (s, 1H), 7.39 (s, 1H), 7.28 (s, 2H), 6.27 
(s, 1H), 6.01 (s, 1H), 4.97 (d, J = 15.5 Hz, 1H), 4.50 (s, 1H), 3.41 (s, 1H), 2.79 (s, 
1H), 2.61 (s, 2H), 2.53 (s, 1H), 2.35 (s, 2H), 2.15 (d, J = 4.7 Hz, 7H), 1.87 (s, 2H), 
1.60 (d, J = 40.8 Hz, 2H), 1.45 (s, 4H), 1.43 – 1.37 (m, 1H), 1.23 (s, 6H), 1.12 (s, 
2H), 0.96 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 206.40, 186.66, 170.38, 
167.71, 156.39, 127.79, 126.55, 125.00, 122.34, 121.34, 120.39, 90.98, 70.32, 
55.32, 51.45, 47.03, 44.13, 40.42, 37.29, 34.76, 33.94, 32.06, 31.35, 24.07, 
21.08, 17.59.  
(6S,9R,10S,11S,13S,16R,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-6,9-
difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-
dodecahydro-3H-cyclopenta[a]phenanthren-3-one (2d): From flumetasone 
using 2-mercaptobenzothiazole to give a white solid in 66% yield. Flash column 
mobile phase 40% EtOAc/hexanes TLC Rf = 0.21 (25% EtOAc/hexanes 
1H NMR 
(500 MHz, Chloroform-d) δ 7.88 (s, 1H), 7.73 (s, 1H), 7.45 (s, 1H), 7.35 (s, 1H), 
7.14 (d, J = 11.5 Hz, 1H), 6.43 (s, 1H), 6.37 (d, J = 12.0 Hz, 1H), 5.37 (d, J = 48.8 
Hz, 1H), 5.12 (s, 1H), 4.42 (s, 1H), 3.38 (s, 1H), 3.18 (s, 1H), 2.77 (s, 1H), 2.47 
(d, J = 54.9 Hz, 2H), 2.27 (s, 1H), 2.17 (s, 1H), 1.75 (s, 1H), 1.59 (s, 1H), 1.54 (s, 





naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (2e): From budesonide using 
2-mercaptobenzothiazole to give a white solid in 70% yield. Flash column mobile 
phase 40% EtOAc/hexanes TLC Rf = 0.20 (25% EtOAc/hexanes 
1H NMR (500 
MHz, Chloroform-d) δ 7.77 (d, J = 24.1 Hz, 2H), 7.39 (s, 1H), 7.28 (s, 2H), 6.24 
(s, 1H), 6.00 (s, 1H), 5.21 (s, 1H), 4.91 (s, 1H), 4.74 (s, 1H), 4.59 (s, 3H), 4.40 (s, 
1H), 2.53 (s, 1H), 2.32 (s, 1H), 2.15 (s, 2H), 2.03 (s, 3H), 1.84 – 1.51 (m, 5H), 
1.39 (s, 5H), 1.13 (s, 2H), 1.04 (s, 1H), 0.99 (s, 2H), 0.93 (d, J = 12.3 Hz, 3H). 
(6aR,7S,8aS,8bS)-8b-(2-(benzo[d]thiazol-2-ylthio)acetyl)-7-hydroxy-
6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-
naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (2f): From desonide using 2-
mercaptobenzothiazole to give a white solid in 66% yield. Flash column mobile 
phase 40% EtOAc/hexanes TLC Rf = 0.21 (25% EtOAc/hexanes 
1H NMR (500 
MHz, Chloroform-d) δ 7.86 (s, 2H), 7.76 (s, 2H), 7.43 (s, 2H), 7.33 (s, 2H), 7.26 
(s, 3H), 6.30 (s, 2H), 6.02 (s, 2H), 5.04 (s, 2H), 4.68 (s, 2H), 4.60 (s, 2H), 4.55 (s, 
2H), 2.54 (s, 3H), 2.34 (ddd, J = 13.5, 4.9, 2.1 Hz, 2H), 2.16 (s, 13H), 1.74 (s, 
3H), 1.60 (s, 5H), 1.46 (s, 12H), 1.25 (s, 1H), 1.22 (s, 3H), 1.14 (s, 8H), 0.98 (s, 
6H). 
Procedure for R2 instillation: The appropriate benzothiazole steroid was 
dissolved in dichloromethane and the solution was cooled to 0 °C. To the cooled 
solution, 1.3 molar equivalents of 4-dimethylaminopyridine (DMAP) was added 
directly followed by the addition of 1.1 molar equivalents of furoyl chloride. The 
reaction was slowly warmed to room temperature and monitored by TLC for 
completion. Once there was no change was seen on the TLC plate after 24 hours 
of stirring the reaction was diluted with dichloromethane and washed in triplicate 
with brine, dried with MgSO4, and filtered. The filtrate was concentrated in vacuo 
and the crude product was purified by column chromatography using 99:1 





dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate (3a): 
From 3a using furoyl chloride to give a white solid in 34% yield. Flash column 
mobile phase 1% CHCl3/methanol TLC Rf = 0.11 (25% EtOAc/hexanes 
1H NMR 
(500 MHz, Chloroform-d) δ 7.80 – 7.69 (m, 2H), 7.59 (dd, J = 1.7, 0.8 Hz, 1H), 
7.39 (dtd, J = 8.3, 7.3, 6.8, 1.3 Hz, 1H), 7.28 (ddd, J = 8.2, 7.3, 1.2 Hz, 3H), 7.25 
– 7.15 (m, 2H), 6.51 (dd, J = 3.5, 1.7 Hz, 1H), 6.35 (ddd, J = 13.8, 10.1, 1.8 Hz, 
1H), 6.14 (dt, J = 14.1, 1.7 Hz, 1H), 4.51 – 4.39 (m, 3H), 3.51 (ddd, J = 10.6, 6.9, 
3.5 Hz, 1H), 2.70 – 2.56 (m, 2H), 2.51 – 2.32 (m, 4H), 1.93 – 1.82 (m, 4H), 1.67 – 
1.51 (m, 5H), 1.41 – 1.28 (m, 2H), 1.28 – 1.22 (m, 1H), 1.17 (s, 3H), 1.04 – 0.99 
(m, 4H), 0.93 – 0.86 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 186.39, 
165.95, 165.66, 158.05, 152.71, 151.68, 147.46, 143.20, 135.61, 130.01, 126.41, 
126.03, 125.25, 124.83, 124.40, 121.25, 121.15, 119.47, 112.17, 100.77, 72.11, 
71.80, 48.63, 48.17, 47.99, 43.73, 37.27, 36.04, 34.07, 33.91, 33.63, 30.91, 




carboxylate (3b): From 2b using furoyl chloride to give a white solid in 34% 
yield. Flash column mobile phase 1% CHCl3/methanol TLC Rf = 0.12 (25% 
EtOAc/hexanes 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.55-1.63 (m, 3H), 
1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26 (m, 1H), 2.33-2.38 
(m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H), 6.08 (s, 1H), 6.95-7.51 
(m, 10H). 1H NMR (500 MHz, Chloroform-d) δ 8.02 – 7.94 (m, 2H), 7.75 – 7.69 
(m, 2H), 7.65 – 7.54 (m, 1H), 7.51 – 7.41 (m, 2H), 7.41 – 7.32 (m, 1H), 7.27 (ddd, 
J = 8.2, 7.2, 1.1 Hz, 1H), 5.72 (d, J = 1.6 Hz, 1H), 4.63 – 4.55 (m, 2H), 4.38 (d, J 
= 17.0 Hz, 1H), 3.12 (ddd, J = 16.2, 11.3, 2.3 Hz, 1H), 2.52 (ddd, J = 18.8, 11.0, 
4.9 Hz, 2H), 2.45 – 2.32 (m, 2H), 2.31 – 2.21 (m, 2H), 2.15 (tdd, J = 13.9, 9.4, 3.3 
Hz, 2H), 2.09 – 1.90 (m, 3H), 1.90 – 1.71 (m, 3H), 1.48 (s, 4H), 1.25 (s, 1H), 1.22 
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– 1.11 (m, 3H), 1.10 (s, 2H). 13C NMR (126 MHz, Chloroform-d) δ 206.34, 
186.59, 152.14, 129.84, 126.71, 126.48, 125.13, 124.99, 124.93, 122.36, 121.34, 
120.42, 90.30, 72.55, 72.24, 68.57, 55.99, 52.09, 48.25, 48.20, 47.57, 43.38, 
40.59, 39.19, 38.39, 37.68, 35.13, 35.08, 34.84, 33.85, 33.80, 33.69, 32.66, 




cyclopenta[a]phenanthren-17-yl furan-2-carboxylate (3c): From 2c using 
furoyl chloride to give a white solid in 30% yield. . Flash column mobile phase 1% 
CHCl3/methanol TLC Rf = 0.10 (25% EtOAc/hexanes). 
1H NMR (500 MHz, 
Chloroform-d) δ 7.77 (s, 2H), 7.59 (s, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.21 (s, 2H), 
6.51 (d, J = 5.2 Hz, 2H), 6.37 (d, J = 10.1 Hz, 2H), 6.14 (d, J = 13.7 Hz, 2H), 5.04 
(d, J = 15.1 Hz, 1H), 4.52 – 4.43 (m, 5H), 3.52 (d, J = 6.9 Hz, 2H), 3.06 (d, J = 
15.1 Hz, 1H), 2.66 – 2.58 (m, 4H), 2.43 (s, 2H), 2.39 (s, 3H), 1.87 (s, 3H), 1.72 
(s, 2H), 1.38 (s, 1H), 1.18 (s, 5H), 1.02 (d, J = 9.0 Hz, 6H), 0.90 (d, J = 7.1 Hz, 
2H). 13C NMR (126 MHz, Chloroform-d) δ 151.57, 147.46, 130.05, 126.03, 
125.28, 124.40, 121.24, 121.16, 119.47, 112.18, 34.08, 33.92, 30.91, 23.02, 




17-yl cyclopenta-1,3-diene-1-carboxylate (3d): From 2d using furoyl chloride to 
give a white solid in 34% yield. Flash column mobile phase 1% CHCl3/methanol 
TLC Rf = 0.11 (25% EtOAc/hexanes 
1H NMR (500 MHz, Chloroform-d) δ 7.78 (dt, 
J = 8.2, 0.9 Hz, 2H), 7.74 – 7.68 (m, 2H), 7.44 – 7.36 (m, 2H), 7.34 – 7.25 (m, 
3H), 7.17 (dd, J = 10.2, 1.5 Hz, 2H), 6.44 (q, J = 1.6 Hz, 2H), 6.36 (dd, J = 10.2, 
1.9 Hz, 2H), 5.44 (ddd, J = 11.7, 6.6, 1.9 Hz, 1H), 5.34 (ddd, J = 11.7, 6.6, 1.9 
Hz, 1H), 5.04 (d, J = 15.1 Hz, 2H), 4.42 (ddd, J = 9.4, 4.0, 2.1 Hz, 2H), 3.21 – 
3.11 (m, 3H), 3.08 (s, 1H), 2.76 (dt, J = 14.4, 3.5 Hz, 2H), 2.59 – 2.49 (m, 2H), 
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2.49 – 2.34 (m, 3H), 2.33 – 2.25 (m, 3H), 1.86 – 1.65 (m, 5H), 1.54 (s, 7H), 1.53 
– 1.45 (m, 2H), 1.32 (ddd, J = 12.0, 8.0, 3.9 Hz, 3H), 1.25 (d, J = 1.8 Hz, 2H), 
1.03 (s, 6H), 0.91 (d, J = 7.1 Hz, 7H). 
2.5.3 Cell culture and glucose-stimulated insulin secretion (GSIS) 
Culture of 832/13 cells and measurements of insulin secretion have been 
described (Hohmeier, Diabetes, 2000). Six-point dose-response curves were 
used to generate EC50 and saturating concentrations of each steroid compound 
(not shown). For GSIS, saturating concentrations of each commercial steroid or 
N-arylpyrazole based steroid were used as indicated in the figure legends. 
2.5.4 Luciferase assays 
832/13 cells were grown in 24-well plates to 50% confluence and then transiently 
transfected with 25 ng of indicated plasmid per well using TransFectin Lipid 
Reagent (Bio-Rad) according to the manufacturer’s instructions. Cell lysis, 
luciferase assays, and normalization to total protein content were carried out as 
described previously (Burke, JBC, 2015). 
2.6 Results 
2.6.1 Non-steroidal glucocorticoids 
Synthetic GCs were tested for their ability to reduce IL-1β-induced inflammation 
(CCL2 assay - transrepression), and their propensity for enhancing transcription 
of a synthetic GRE-containing promoter luciferase reporter gene (3xGRE assay - 
transactivation). Compounds providing the desired dissociated profile reduce 
inflammation with reduced transactivation compared to dexamethasone. 
Unfortunately for most of the compounds that exhibit transrepression, they also 
enhance transactivation presumably through direct binding of GR-GC complex to 
the nuclear GRE, thereby enhancing the transcription of pro-inflammatory 
cytokines. This increase in transactivation also seems to be influenced by GCs 
whose sidegroup can participate in π-π interactions with a bound GR. Two of the 
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compounds 11aa and 13aa synthesized and screened for their therapeutic profile 
showed the desired activity. (Figure 23) CCL2 and 3xGRE assay data for all 
tested compounds can be found in the chapter Appendix 2.8. Three different 
sets of GC analogues with respect to the installed headgroup (R1) were tested for 
biological activity, and the 4-fluorophenyl series was observed to have the 
greatest dissociated profile. Transrepression commenced at nM and µM 
concentrations with ~70% reduction in relative promoter activity for the higher 
concentrations of fluorophenyl GCs. Compounds with the greatest observed 
transrepression were those whose sidegroup (R2) possesses a delocalized 
system of π-electrons (R2 = phenyl, 4-fluorophenyl, 1,2-difluoroanisolyl, and 3-
thiophenyl). The observed activity is likely a function of hydrophobic interactions 
between GC and bound GR. GCs with R2 moieties of smaller (methyl-), and 
larger (cyanomethyl-) steric bulk that do not bear any delocalized π-electrons 
show a significant decrease in desired activity, suggesting that size of the R2 
group has little influence on biological response – but rather that electronic 
interactions between GC and GR are more impactful. 
Within the 4-fluorophenyl headgroup compound series, transactivation was 
increased again with analogues bearing an R2 moiety having delocalized system 
of π-electrons. Transactivation is observed at GC concentrations ranging from 
nM to µM, where there is differential activity between molecule sets 11 and 13 
having the same sidegroup. The additional steric bulk around the alcohol 
introduced by a methyl group in compound series 13 seems to enhance 
transrepression but also has an upregulating influence on transactivation, which 
makes series 13 less therapeutically valuable than the series 11 analogues. The 
intermediate ketone series 12aa-12ag was tested for biological activity, but was 
found to enhance transactivation more than transrepression, indicating the 
alcohol group of series 11 and 13 analogues being important in influencing 
transrepressive activity of these molecules. It seems that coordination of the 
alcohol and/or an electron rich aromatic R2 group in the GR binding pocket elicit 




Figure 23: Non-steroidal glucocorticoid scaffold analogue data 




series 12 (excluding analogues 12aa-12ag) were not subjected to biological 
testing. 
Both 1-(4-methoxyphenyl) and 1-(4-methylphenyl) headgroup analogues did not 
show a significant decrease in transrepression or an increase in transactivation, 
except for compounds whose R2 moiety contains delocalized π-electrons. For 
those compounds, transrepression was diminished only at ~µm concentrations, 
and an increase in transactivation was only observed at high GC concentration 
(≥µM). This difference in activity compared to the 4-fluorophenyl headgroup 
series may be attributable to differential solubility between the analogues, being 
that fluorinated drugs are known for their increased lipid-solubility making them 
more easily transported throughout the cell.117 Data from the inflammatory 
assays portend that compared to the R1 = 1-(4-methoxyphenyl)- / 1-(4-
methylphenyl)-GCs, the R1 = 1-(4-fluorophenyl) series would appear to have a 
greater affinity for the hGR, or may just be more easily transported throughout 
the cell due to solubility properties compared to the other GC analogues. Binding 
affinity calculations (Appendix 2.8.7) for all tested compounds reveal similar 
affinities to the hGR (5NFP) with an average binding affinity of -9.5 ±1.75 
kcal/mol. This may suggest some of the observed differences in biological activity 
for the R1 = 1-(4-fluorophenyl) series as being a function of bioavailability.  
An increase in transactivation is an undesired effect of these drug candidates, 
and this activity is enhanced in compounds containing an aromatic sidegroup 
(R2); Although, the modeled binding patterns within the hGR between the R2 
analogues are similar, the aromatic sidegroups may generate strong π-π 
interactions not accounted for with a non-flexible receptor model, which may be 
an important factor in enhancing transactivation.  There is also an observable 
trend in which series 13 compounds have a higher average affinity for the hGR 
than series 11, which may explain why compounds 12 and 13 exhibit stronger 
transactivating activity when compared to 2˚OH series 11. The differential activity 
observed between compounds bearing different R1 headgroups as suggested 
before may be attributable to differences in bioavailability, but when considering 
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the binding features in the R1 = 1-(4-fluorophenyl) series, there is a hydrophilic 
interaction with residue Ala605 in nearly all instances, especially among the 
molecules conferring the desired therapeutic profile. 
2.6.2 Steroidal glucocorticoids  
The steroidal glucocorticoid scaffolds analogues were synthesized to study the 
effect of structural modifications to the steroid ring structure attempting to find 
molecules possessing varying structure-activity relationships to improve 
therapeutic value of glucocorticoid drugs. 2-Mercaptobenzothiazole modifications 
to the steroid ring structure were previously reported as having dissociating 
activities separating transrepression from transactivation.56, 111 However only 
hydrocortisone was subjected to testing dissociating activities and the results 
were quite promising. Due to hydrocortisone’s improved IL-6 inhibition as well as 
inhibiting transactivation potential multiple more synthetic steroids were 
subjected to derivatization with 2-mercaptobenzothiazole and 2-furoyl groups at 
R1 and R2 respectively. (Figure 24) 
The synthetic steroids that were subjected to derivatization were 
dexamethasone, betamethasone, prednisolone, flumetasone, budesonide, and 
desonide. They were chosen due to their wide use in medicinal chemistry and 
well-known enhancers of transactivation activity properties. The compounds were 
tested for their ability to suppress or activate transactivation coming from a 
promoter with three copies of the census glucocorticoid-response element 
(3xGRE) as well as the ability to repress IL-1β mediated increase in the CCL2 
gene transcription. The gene expression of CCL2 causes macrophages, T-
lymphocytes and monocytes to travel to sites of inflammation sites and is 
increased in both β-cells and adipose tissue. All steroid backbones tested 
showed the ability to repress IL-1β simulated CCL2 gene transcription 
(Appendix 2.8.10) with flumetasone displaying the most favorable 




Figure 24: Steroidal scaffold 
 
 
backbone was also observed in the 3xGRE containing promoter construct. This 
result of the increased transrepression and transactivation activity was expected 
in the steroid backbones as a dissociated profile is sought upon derivatization. Of 
all the steroid derivatives tested 3d and 3c displayed the most favorable profile 
across all concentrations. (Figure 25) 
The remaining derivatives that displayed positive results were 3a and 3b, they 
showed the ability to repress the cytokine at 0.1nM by 45% and 55% 
respectively. The first derivatization of the steroid scaffold with 2-
mercaptobenzothiazole proved to have a negative result when compared to the 
steroid backbone in each GC tested (2a-2f) (Appendix 2.8) The second 
derivatization with the 2-furoyl group saw the transrepressive ability of the 
analogues improve across all steroid backbones tested (3a-3d). (Figure 26) 
The dexamethasone and betamethasone derivatives 3a and 3b saw no 
improvement over their original steroid backbone tested. Prednisolone saw a 
greatly improved ability to repress the cytokine across all concentrations in 
derivative 3c. The second derivative of flumetasone 3d was by far the best 
candidate tested in the CCL2 assay, repressing over 65% of the response from 
the cytokines at 0.1 nM. The inability for prednisolone to repress the activity of 
the cytokine at low concentrations is unlike other steroid backbones tested. It 
could be hypothesized the C-16 methylation can prove vital to the activity, 
because prednisolone is the one backbone tested with the absence of a methyl 












at R2 (Figure 27) to conclude if the ability to repress the cytokine is improved by 
the single modification of 2-furoyl or does the combination of the two 
derivatizations lead to the transrepressive bioactivity. The 2-
mercaptobenzothiazole modification did not help the steroids ability to repress 
the IL-6β cytokine but it did show the ability to inhibit the dimerization of the GR 
across 4 of the 5 scaffolds tested. Desonide was the only scaffold that did not 
show an improved transactivating profile after the first derivatization. A derivative 
of budesonide was also made containing the modification with 2-
mercaptobenzothiazole although it had not been tested yet. Budesonide and 
desonide make up a subclass of acetonide glucocorticoids that contain a 
heterocyclic acetal between carbon C-16 and C-17. This could be hypothesized 
that the hydroxyl group at C-17 in combination with 2-mercaptobenzothiazole is 
leading to the ability to inhibit the dimerization of the receptor. The two analogues 
synthesized that tested the best in the 3xGRE promoter assay were 2b and 2c. 
(Figure 27).  
The greatly improved transactivation profiles of 2b and 2c displayed the ability to 
inhibit promoter activity 4 times better at 0.1 nM than the steroid backbone. 2c 
was the overall best analogue as it displayed little promoter activity over the 
control at concentration up to 100 nM. Further indication that the C-17 hydroxyl 
group is important to preferred transactivating properties is shown through the 
second derivatization with 2-furoyl. The addition of the 2-furioyl group negatively 
impacts all the steroid scaffold tested in terms of transactivating profile, although 
still better than the original steroid backbone. Flumetasone, known as one of the 
strongest synthetic glucocorticoids is only used in a medicinal setting due to the 
side effects of the drug heightened. Its derivatization with 2-
mercatptobenzothiazole saw 5-fold improvement at 0.1nM over the steroid 
backbone and less than a 5-fold promoter activity over the control across all 
concentrations up to 10 μM.  
Selective compounds were subjected to a screen of additional genes using 








 secretion. The gene of interest SGK1 (serum and glucocorticoid-inducible kinase 
1) displayed a 10-fold change in mRNA by dexamethasone at 6 nM, but 2a, and 
3a only shoed a 2-fold increase at the same concentration. Betamethasone 
derivatives subjected to screening of SGK1 showed the steroid derivatives have 
a relative promoter activity 5 to 6 times lower than steroid scaffold. Prednisolone 
derivatives continued to show the most promise as a future therapeutic agent as 
gene studies of SGK1 shoed a relative mRNA abundance increases 2-fold for 2c, 
only slightly less effective than the steroid scaffold. Although flumetasone did not 
display a dissociated profile for its anti-inflammatory, its relative mRNA 
abundance in SGK1 studies for the first derivatization increases 5-fold in 832/13 
rat insulinoma cells, compared to 6-fold in flumetasone. Budesonide derivative 2f 
did not increase relative mRNA abundance.  
2.7 Conclusion 
Glucocorticoids are lipophilic compounds that target the GR impacting multiple 
cellular processes including in the immune system, lipid and glucose 
homeostasis and reproductive function. The variety of cellular processes 
manipulated by steroidal or non-steroidal GC’s makes it useful across clinical 
settings. Although they are very effective to treat the underlying cause, long time 
use of GC’s produce a hoard of undesired side effects.111 This has led to the 
search for new GC’s that retain its therapeutic index with less side effects. We 
have developed a series of steroidal and non-steroidal GC’s that have the 
desired anti-inflammatory profile and haven’t been tested before using rodent 
and human islets β-cell lines. The steroidal GC’s derivatized with 2-
mercaptobenzothiazole, 2a, 2b, and 2c all displayed impressive transactivating 
profiles. The molecules that were synthesized with both the 2-
mercaptobenzothiazole and 2-furoyl groups, 3c and 3d displayed impressive 
transrepressive profiles. There is a clear distinction is the transcription ability of a 
steroidal glucocorticoid upon derivatization with 2-mercaptobenzothiazole. The 
addition of the heterocycle to a commercially available steroidal scaffold retained 
135 
 
desirable transrepressive properties of the steroid as well as improved the 
transactivation potential across all scaffolds tested. The findings in this study of 
steroidal derivatization can aid future GC drug targets considering the properties 
observed derivatizing C17 of the steroid backbone. The limitation of the study on 
the steroidal glucocorticoids is that no current data on insulin suppression has 
been acquired thus far. Commercial GC’s have the tendency to impair insulin 
sensitivity in both skeletal and liver muscle, adipose tissue and impair β-cell 
function, therefore additional experiments will need to address these issues. 2a, 
2b, 2c, 3c and 3d are prime candidates for insulin secretion experiments as they 
have displayed the more favorable anti-inflammatory profile. 
The non-steroidal glucocorticoids were all subjected to testing anti-inflammatory 
activity as well as the top candidates moving forward to insulin secretion testing. 
The transcription properties of the compounds where tested and compared to 
dexamethasone for transrepressive and transactivating potential. When 
comparing the compounds to dexamethasone for repression of IL-1β-mediated 
increase in CCL2 gene expression the synthetic glucocorticoid showed minimal 
improvement over dexamethasone. The transcription of the 3xGRE containing 
promoter construct was compared between dexamethasone and the synthetic 
non-steroidal GC’s with the results generating two molecules containing a 
desirable profile. 30 of the 32 compounds were found to drive transactivation 
potential of the 3xGRE comparable to dexamethasone. The two compounds that 
did not express any transactivation potential were compounds 11aa and 11ab. 
The dissociated transcription profile of 11aa and 11ab are desired for clinical 
applications. The compounds were then subjected to insulin secretion testing 
comparing the synthetic GC’s to DMSO and dexamethasone at 3- and 15-mM 
concentrations. 11aa induced a 1.5-fold increase over dexamethasone in terms 
of insulin secretion, while 13aa displayed little improvement over 
dexamethasone. Molecular modeling of the non-steroidal GC’s reveals the 
beneficial interactions with the human glucocorticoid receptor that may be 
applied in future endeavors with this molecular scaffold.  
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The comparison of the structural-activity relationship of the GC-GR between the 
synthetic steroidal and non-steroidal compounds in the study is dampened 
because of the absence of insulin secretion data on steroidal compounds. 
Although comparisons can be made of the structure-activity relationship of the 
anti-inflammatory properties between the compounds. The addition of steric bulk 
in both compounds eventually led to an unfavorable profile. For the steroidal 
GC’s, the second derivatization with furoyl added caused unfavorable activity. As 
for the non-steroidal GC’s the addition of any bulk caused transactivation 
potential. The steric bulk likely caused disruption of the hydrogen bonding of the 
C21 hydroxyl group.  
In summary the glucocorticoids synthesized and purified showed potential usage 
as a general anti-inflammatory drug or used as a specific compound for targeted 
treatment of existing conditions. Of the 42 glucocorticoids synthesized, 5 
compounds displayed the dissociated transcription profile desired increasing 
CCL2 gene transcription as well as refraining from increasing 3xGRE promoter 
activity. The compounds containing the desired profile we found to be 2a, 2b, 2c, 
3c, 3d, 11aa and 13aa. Future work targeting the GR can benefit from some of 
the structure-activity relationships that we have observed.   
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2.8 Chapter II Appendix 





























[1,3]dioxolane] (7a): 1H-NMR (CDCl3, 499.73 MHz) δ 1.21 (s, 3H), 1.65-1.82 (m, 
4H), 2.27-2.30 (d, 1H), 2.42-2.52 (m, 2H), 3.14-3.17 (d, 1H), 3.97-4.10 (m, 4H), 
6.20 (s, 1H), 7.14 (m, 2H), 7.41-7.44 (m, 3H). 
1-(4-fluorophenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one 
(8a): 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.63-1.72 (m, 1H), 2.06-2.12 
(m, 1H), 2.51-2.57 (m, 2H), 2.60-2.69 (m, 2H), 2.87-2.91 (s, 2H), 6.29 (s, 1H), 
7.15-7.18 (t, 2H), 7.44-7.47 (m, 2H), 7.48 (s, 1H). 
1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-
carbaldehyde (10a): 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.35-1.45 (m, 
2H), 1.68-1.77 (m, 1H), 1.89-1.95 (m, 2H), 2.32-2.42 (m, 3H), 2.87-2.90 (d, 1H), 
3.07-3.10 (d, 1H), 6.18 (s, 1H), 7.12-7.16 (t, 2H), 7.41-7.44 (m, 3H), 9.93 (s, 1H). 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)ethan-1-ol (11aa): 1H-NMR (CDCl3, 499.73 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d, 
3H), 1.41-.147 (dd, 2H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.90-1.97 (m, 
1H), 2.31-2.43 (m, 2H), 2.46-2.52 (d, 1H), 2.98-3.03 (d, 1H), 4.25 (s, 1H), 6.10 (s, 
1H), 7.11-7.19 (m, 2H), 7.41-7.47 (m, 3H). 
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13aa): 1H-NMR (CDCl3, 300.08 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d, 
3H), 1.35-1.47 (m, 2H), 1.58 (s, 3H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.89-
1.98 (m, 1H), 2.26-2.42 (m, 2H), 2.46-2.52 (d, 1H), 2.98-3.03 (d, 1H), 6.10 (s, 
1H), 7.12-7.18 (m, 2H), 7.41-7.47 (m, 3H). 
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(phenyl)methanol (11ab): 1H-NMR (CDCl3, 499.73 MHz) δ 1.18 (s, 3H), 1.52-
1.58 (m, 2H), 1.60-1.63 (dd, 1H), 1.70-1.74 (m, 2H), 2.17-2.21 (m, 1H), 2.28-2.36 
(m, 1H), 2.66-2.69 (d, 1H), 3.08-3.11 (d, 1H), 5.10 (d, 1H), 6.02 (s, 1H), 7.04-7.08 




1-phenylethan-1-ol (13ab): 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 1.56-
1.65 (m, 2H), 1.67 (s, 3H), 1.74-1.80 (m, 1H), 2.02-2.08 (dd, 1H), 2.23-2.44 (m, 
2H), 2.58-2.64 (d, 1H), 3.12-3.17 (d, 1H), 6.09 (s, 1H), 7.10-7.16 (t, 2H), 7.27-
7.52 (m, 8H). 
(4-fluorophenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11ac): 1H-NMR (CDCl3, 300.08 MHz) δ1.26 (s, 
3H), 1.65-1.69 (m, 3H), 1.77-1.86 (m, 1H), 2.26-2.41 (m, 2H), 2.72-2.77 (d, 1H), 
3.17-3.22 (d, 1H), 5.19-5.22 (s, 1H), 6.12 (s, 1H), 7.02-7.08 (t, 2H), 7.13-7.19 (t, 
2H), 7.30-7.34 (dd, 2H), 7.44-7.48 (m, 3H). 
1-(4-fluorophenyl)-1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)ethan-1-ol (13ac): 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 
3H), 1.51-1.62 (m, 2H), 1.66 (s, 3H), 1.72-1.81 (m, 2H), 1.95-2.05 (m, 1H), 2.21-
2.40 (m, 2H), 2.58-2.64 (d, 1H), 3.14-3.20 (d, 1H), 6.09 (s, 1H), 7.00-7.06 (t, 2H), 
7.11-7.17 (t, 2H), 7.25-7.28 (m, 1H), 7.41-7.49 (m, 4H). 
(3,4-difluoro-5-methoxyphenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)methanol (11ad): 1H-NMR (CDCl3, 300.08 
MHz) δ 1.26 (s, 3H), 1.54-1.57 (m, 1H), 1.64-1.72 (m, 1H), 1.82-1.86 (m, 2H), 
2,28-2.46 (m, 3H), 2.72-2.77 (d, 1H), 3.17-3.22 (d, 1H), 3.92 (s, 3H), 5.12 (s, 1H), 
6.12 (s, 1H), 6.72-6.80 (m, 2H), 7.15-7.21 (m, 2H), 7.45-7.54 (m, 3H). 
1-(3,4-difluoro-5-methoxyphenyl)-1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13ad): 1H-NMR (CDCl3, 499.73 
MHz) δ 1.26 (s, 3H), 1.54-1.60 (m, 2H), 1.62 (s, 3H), 1.64-1.66 (m, 1H), 1.80-
1.85 (m, 1H), 1.96-1.99 (dd, 1H), 2.24-2.30 (m, 1H), 2.34-2.42 (m, 1H), 2.57-2.60 
(d, 1H), 3.07-3.11 (d, 1H), 3.91 (s, 3H), 6.10 (s, 1H), 6.87-6.91 (m, 2H), 7.12-7.16 
(t, 2H), 7.28 (s, 1H), 7.42-7.45 (m, 2H). 
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-3-yl)methanol (11ae): 1H-NMR (CDCl3, 499.73 MHz) δ 1.24 (s, 3H), 
1.65-1.93 (m, 5H), 2.27-2.48 (m, 2H), 2.67-2.72 (d, 1H), 3.08-3.15 (d, 1H), 5.24 
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(s, 1H), 6.12 (s, 1H), 6.94-6.99 (m, 1H), 7.12-7.24 (m, 3H), 7.30-7.33 (m, 1H), 
7.43-7.48 (m, 3H). 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-
1-(thiophen-3-yl)ethan-1-ol (13ae): 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 
1.52-1.62 (m, 3H), 1.68 (s, 3H), 2.01-2.06 (m, 1H), 2.24-2.43 (m, 3H), 2.64-2.69 
(d, 1H), 3.24-3.30 (d, 1H), 6.10 (s, 1H), 7.14-7.17 (m, 3H), 7.27-7.30 (m, 1H), 
7.33 (s, 1H), 7.42-7.47 (m, 3H). 
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-
3-hydroxypropanenitrile (11af): white solid obtained in 46% yield; mp 121-123.8 
˚C; TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.14; [α]D
20 = +60 (c 
1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.04-1.13 (s, 3H), 1.25-1.46 (m, 
2H), 1.61-1.71 (m, 2H), 1.78-1.97 (m, 2H), 2.30-2.42 (m, 2H), 2.47-2.72 (m, 3H), 
2.93-3.21 (d, 1H), 4.16-4.40 (m, 1H), 6.12 (s, 1H), 7.14-7.44 (m, 5H); 13C-NMR 
(CDCl3, 125.66 MHz) δ 19.32, 20.91, 25.37, 26.20, 32.98, 33.19, 34.64, 52.82, 
66.62, 109.76, 115.96, 116.14, 125.32, 137.86; IR (NaCl, thin film) νmax (cm
-1): 
3335 (OH), 3030 (w), 2934, 2867, 2249 (CN), 1619, 1518, 1225, 840; HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C21H23FN3O, 352.18197; found 352.18293. 
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-
3-hydroxybutanenitrile (12af):  white solid obtained in 16% yield; mp 120-129 ˚C; 
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.11; [α]D
20 = +60 (c 1.0, 
CHCl3); 
1H-NMR (CDCl3, 499.73 MHz) δ 1.20 (s, 3H), 1.45-1.49 (m, 2H), 1.82-
1.87 (t, 2H), 1.93-1.97 (d, 1H), 2.32-2.44 (m, 3H), 2.74-2.77 (d, 1H), 2.82-2.88 
(m, 2H), 3.53-3.61 (s, 2H), 6.15 (s, 1H), 7.14-7.44 (m, 5H); 13C-NMR (CDCl3, 
125.66 MHz) δ 18.53, 25.21, 25.61, 31.72, 33.85, 34.75, 41.16, 59.60, 110.18, 
112.91, 113.49, 116.00, 135.61, 136.29, 137.72, 146.60, 160.56, 162.53, 199.38; 
IR (NaCl, thin film) νmax (cm
-1) 2955, 2920, 2850, 1723 (m), 1514 (m), 1462, 
1377, 1222; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H21FN3O, 
350.16632; found 350.16529. 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-
2,2-dimethylpropan-1-ol (11ag): 1H-NMR (CDCl3, 499.73 MHz) δ 0.97 (s, 9H), 
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1.08 (s, 3H), 1.38-1.45 (m, 1H), 1.59-1.67 (m, 1H) 1.72-1.79 (m, 2H), 1.83-1.87 
(m, 1H), 2.30-2.35 (m, 1H), 2.36-2.44 (m, 1H), 2.45-2.48 (d, 1H), 2.82-2.85 (d, 
1H), 3.50 (s, 1H), 6.13 (s, 1H), 7.13-7.17 (t, 2H), 7.41 (s, 1H), 7.43-7.47 (m, 2H). 
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-
3,3-dimethylbutan-2-ol (12ag): beige solid obtained in 14% yield; mp 98 - 101˚C; 
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.54; [α]D
20 = +8.7 (c 1.0, 
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 9H), 1.33 (s, 3H), 1.40-1.50 (m, 
1H), 1.55 (s, 1H), 1.70-1.74 (dd, 1H), 2.27-2.33 (m, 1H), 2.42-2.53 (m, 1H), 2.56-
2.68 (m, 2H), 3.08-3.13 (m, 1H), 6.11 (s, 1H), 7.12-7.18 (t, 2H), 7.36 (s, 1H), 
7.42-7.46 (dd, 2H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.22, 26.03, 27.02, 27.50, 
31.99, 34.63, 41.82, 45.42, 53.04, 109.06, 113.60, 115.92, 119.70, 125.32, 
135.81, 136.61, 137.77, 149.32, 160.46, 162.43, 218.05; IR (NaCl, thin film) νmax 
(cm-1) 2927, 2855, 1699, 1516, 1479, 1464, 1375, 1366, 1292, 1224, 1176, 1152, 




[1,3]dioxolane] (7b): 1H-NMR (CDCl3, 300.08 MHz) δ 1.14 (s, 3H), 1.56-1.79 (m, 
5H), 2.19-2.22 (m, 1H), 2.32 (s, 3H), 2.42-2.45 (d, 1H), 3.08-3.11 (d, 1H), 3.92-
4.01 (m, 4H), 6.18 (s, 1H), 7.17-7.19 (m, 2H), 7.27-7.29 (m, 2H), 7.33 (s, 1H). 
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8b): 1H-
NMR (CDCl3, 300.08 MHz) δ 1.24 (s, 3H), 1.59-1.79 (m, 2H), 2.03-2.13 (m, 1H), 
2.40 (s, 3H), 2.49-2.70 (m, 3H), 2.90 (s, 2H), 6.32 (s, 1H), 7.26-7.28 (m, 2H), 
7.35-7.38 (m, 2H), 7.47 (s, 1H). 
4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-
carbaldehyde (10b): 1H-NMR (CDCl3, 300.08 MHz) δ 1.12 (s, 3H), 1.33-1.50 (m, 
1H), 1.67-1.76 (m, 1H), 1.81-1.98 (m, 2H), 2.34-2.46 (m, 6H), 2.88-2.94 (d, 1H), 
3.08-3.13 (d, 1H), 6.21 (s, 1H), 7.25-7.28 (m, 2H), 7.34-7.37 (m, 2H), 7.43 (s, 




ol (11ba): white solid obtained in 50% yield; mp 178.1-181.0 ˚C; TLC (Silica G 
w/UV254) 30% EtOAc in hexanes, Rf = 0.16; [α]D
20 = -16 (c 1.0, MeOH); 1H-NMR 
(CDCl3, 499.73 MHz) δ 1.13 (s, 3H), 1.23-1.29 (m, 3H), 1.34-1.45 (m, 2H), 1.56-
1.62 (m, 2H), 1.72-1.78 (m, 1H), 1.90-1.94 (m, 1H), 2.27-2.30 (m, 1H), 2.32-2.37 
(m, 4H) 2.47-2.50 (d, 1H), 2.97-3.00 (d, 1H), 6.14 (s, 1H), 7.23-7.26 (d, 2H), 
7.34-7.36 (d, 2H), 7.40 (s, 1H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.21, 20.81, 
24.34, 25.85, 33.32, 34.67, 41.14, 54.89, 56.00, 66.11, 109.50, 113.47, 123.47, 
129.65, 136.81, 137.28, 137.60, 149.57; IR (NaCl, thin film) νmax (cm
-1): 3315 
(OH), 3043 (w), 2962, 2936, 2862, 1620, 1518 (w), 1425, 1132, 820; HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C21H27N2O, 323.21179; found 323.21001. 
2-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13ba): white solid obtained in 55% yield; mp 173-176 ˚C; TLC 
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.17; [α]D
20 = -75 (c 1.0, MeOH); 
1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 3H), 1.33-1.37 (s, 8H), 1.38-1.39 (d, 
1H), 1.66-1.69 (d, 1H), 1.77-1.80 (dt, 1H), 1.84-1.87 (dt, 1H), 2.31 (m, 1H), 2.39 
(s, 3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 6.16 (s, 1H) 7.24-7.25 (d, 2H), 7.35-
7.38 (d, 2H), 7.40 (s, 1H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.65, 26.38, 27.48, 
29.70, 33.91, 34.52, 36.19, 43.57, 57.61, 75.52, 109.76, 115.22, 123.26, 129.63, 
136.59, 137.38, 150.95; IR (NaCl, thin film) νmax (cm
-1): 3395 (OH), 2928, 2855, 
1611 (w), 1519 (m); HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C22H29N2O, 
337.2274; found 337.2200. 
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(phenyl)methanol (11bb): white solid obtained in 28% yield; mp 184-187 ˚C; 
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.20; [α]D
20 = -12 (c 1.0, 
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.60-1.81 (m, 5H), 2.23-
2.28 (d, 1H), 2.36-2.43 (m, 4H), 2.74-2.77 (d, 1H) 3.15-3.18 (d, 1H), 5.17 (s, 1H), 
6.15 (s, 1H), 7.23-7.27 (d, 3H), 7.34-7.38 (m, 6H), 7.41 (s, 1H); 13C-NMR (CDCl3, 
125.66 MHz) δ 19.90, 21.05, 25.79, 41.28, 56.66, 71.95, 109.51, 113.67, 123.52, 
125.38, 126.78, 128.16, 129.68, 137.60, 145.70, 149.77; IR (NaCl, thin film) νmax 
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(cm-1): 3319 (OH), 3039 (w), 2929, 2868, 1610 (w), 1519 (m), 821; HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C26H29N2O, 385.22744; found 385.22612. 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
phenylethan-1-ol (13bb): white solid obtained in 82% yield; mp 172-174.5 ˚C; 
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.27; [α]D
20 = -26 (c 1.0, 
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 1.62-1.66 (m, 2H), 1.68 (s, 
3H), 1.74-1.79 (m, 2H), 2.04-2.07 (d, 1H), 2.24-2.28 (d, 1H), 2.33-2.40 (m, 4H), 
2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 6.14 (s, 1H), 7.23-7.29 (m, 4H), 7.33-7.36 
(m, 4H), 7.49-7.52 (m, 2H); 13C-NMR (CDCl3, 125.66 MHz) δ 20.41, 21.02, 
25.82, 26.11, 28.40, 29.68, 34.20, 35.90, 44.00, 56.78, 78.79, 109.52, 115.37, 
123.26, 125.56, 126.74, 128.02, 129.62, 136.05, 136.53, 137.41, 137.72, 151.03; 
IR (NaCl, thin film) νmax (cm
-1): 3365 (OH), 3054 (w), 2928, 2858, 1610 (w), 1519 
(m), 821; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C27H31N2O, 399.2430; found 
399.2368. 
(4-fluorophenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-
5-yl)methanol (11bc): white solid obtained in 11.5% yield; mp 188-191 ˚C; TLC 
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.24; [α]D
20 = -24 (c 1.0, MeOH); 
1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.50-1.61 (m, 3H), 1.67-1.71 (m, 
2H), 1.79-1.82 (d, 1H), 2.25-2.28 (d, 1H), 2.39 (s, 3H), 2.74-2.77 (d, 1H), 3.16-
3.20 (d, 1H), 5.19 (s, 1H), 6.16 (s, 1H), 7.02-7.46 (m, 9); 13C-NMR (CDCl3, 
125.66 MHz) δ19.19, 21.04, 25.74. 33.25, 35.24, 41.24, 56.75, 71.47, 109.62, 
113.54, 114.58, 123.50, 126.92, 129.69, 136.68, 136.90, 137.23, 137.58, 141.26, 
149.48, 160.71, 162.66; IR (NaCl, thin film) νmax (cm
-1): 3312 (OH), 3041 (w), 
2931, 2867, 2830, 1898, 1603, 1518, 1219, 819; HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C26H28FN2O, 403.21802; found 403.21649. 
1-(4-fluorophenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)ethan-1-ol (13bc): white solid obtained in 80% yield; mp 
188.5-191 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.25; [α]D
20 = 
-9 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.60-1.63 (m, 
3H), 1.66 (s, 3H), 1.75-1.79 (d, 1H), 1.99-2.02 (d, 1H), 2.24-2.27 (d, 1H), 2.39 (s, 
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3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 5.30 (s, 1H), 6.14 (s, 1H), 7.01-7.48 (m, 
9H); 13C-NMR (CDCl3, 125.66 MHz) δ 20.40, 21.02, 25.83, 26.16, 28.41, 34.15, 
36.03, 43.98, 56.89, 78.55, 109.60, 114.59, 115.25, 123.26, 127.24, 129.63, 
136.58, 137.69, 150.94; IR (NaCl, thin film) νmax (cm
-1): 3315 (OH), 3020 (w), 
2928, 2860, 1600, 1519, 1222; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for 
C27H30FN2O, 417.23367; found 417.23232. 
(3,4-difluoro-5-methoxyphenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11bd): white solid obtained in 76% yield; mp 97-
101 ˚C; TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.22; [α]D
20 = +31 
(c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (m, 3H), 1.37-1.50 (m, 2H), 
1.54-1.65 (m, 2H), 1.76-1.79 (d, 1H), 2.04 (s, 3H), 2.26-2.29 (d, 1H), 2.72-2.75 
(d, 1H), 3.14-3.17 (d, 1H), 3.88 (s, 3H), 5.10 (s, 1H), 6.16 (s, 1H), 6.72-6.78 (m, 
2H), 7.24-7.46 (m, 6H); 13C-NMR (CDCl3, 125.66 MHz) δ 14.18, 19.94, 21.04, 
25.70, 33.17, 35.31, 41.20, 56.71, 60.38, 71.28, 105.52, 106.04, 109.70, 113.35, 
123.36, 129.66, 136.67, 136.99, 137.17, 137.55, 149.25; IR (NaCl, thin film) νmax 
(cm-1): 3387 (OH), 3050 (w), 2927, 2850, 1623, 1522, 1454, 1426, 1339, 1226, 
1097; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O2, 451.21916; 
found 451.21790.  
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13bd): white solid obtained in 
94% yield, mp 181-183 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 
0.19; [α]D
20 = +13 (c 3.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.22-1.35 (m, 
6H), 1.58-1.62 (m, 4H), 1.79-1.83 (d, 1H), 1.96-1.99 (d, 1H), 2.25-2.28 (d, 1H), 
2.34-2.44 (s, 3H), 2.57-2.61 (d, 1H), 3.05-3.08 (d, 1H), 3.91-3.96 (s, 3H), 6.15 (s, 
1H), 6.87-6.92 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (s, 1H); 13C-NMR (CDCl3, 125.66 
MHz) δ 20.53, 25.64, 26.24, 28.90, 33.96, 35.77, 44.02, 56.34, 123.27, 129.65, 
136.66; IR (NaCl, thin film) νmax (cm
-1): 3348 (OH), 2927, 2853, 1622, 1520, 
1451, 1420, 1334, 1228, 1101; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for 




2-yl)methanol (11be): white solid obtained in 36% yield; mp 109-114 ˚C; TLC 
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.26; [α]D
20 = -17 (c 1.0, MeOH); 
1H-NMR (CDCl3, 499.73 MHz) δ 1.23 (s, 3H), 1.62-1.91 (m, 6H), 2.26-2.31 (m, 
1H), 2.40 (s, 3H), 2.67-2.72 (m, 1H), 3.06-3.14 (m, 1H), 5.39 (s, 1H), 6.16 (s, 
1H), 6.95-7.43 (m, 8H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.07, 21.03, 21.64, 
23.60, 24.35, 25.83, 33.32, 33.51, 34.67, 35.08, 40.64, 41.13, 54.89, 56.02, 
66.12, 67.89, 109.57, 114.13, 123.42, 129.65, 136.46, 137.59, 149.61; IR (NaCl, 
thin film) νmax (cm
-1): 3319 (OH), 3106 (w), 3045 (w), 2928, 2856, 2836, 1611, 
1540 (m); HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C24H27N2OS, 391.18386; 
found 391.13976. 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
(thiophen-2-yl)ethan-1-ol (13be): white solid obtained in 76% yield; mp 90-95 ˚C; 
TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.28; [α]D
20 = -12 (c 3.0, 
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.40-1.41 (d, 1H), 1.57-
1.59 (d, 1H), 1.65 (s, 3H), 1.69-1.70 (d, 2H), 1.76-1.78 (d, 1H), 2.03-2.06 (d, 1H), 
2.26-2.28 (d, 1H), 2.39 (s, 3H), 2.66-2.69 (d, 1H), 3.22-3.25 (d, 1H), 6.15 (s, 1H), 
7.12-7.37 (m, 8H); 13C-NMR (CDCl3, 125.66 MHz) δ 20.13, 21.02, 26.16, 28.19, 
29.68, 34.31, 35.80, 43.88, 56.70, 109.66, 115.39, 119.69, 123.26, 125.64, 
126.49, 129.63, 136.56, 137.73, 150.91; IR (NaCl, thin film) νmax (cm
-1): 3381 
(OH), 3105 (w), 3042 (w), 2928, 2859, 1611, 1518 (m), 821; HRMS (DART-
RTOF) m/z: [M+H]+ Calcd for C25H29N2OS, 405.1995; found 405.1997. 
4-methoxyphenyl analogues 
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydrospiro[benzo[f]indazole-
5,2'-[1,3]dioxolane] (7c): 1H-NMR (CDCl3, 300.08 MHz) δ 1.21 (s, 3H), 1.64 (m, 
2H), 1.84 (m, 2H), 2.24-2.30 (m, 1H), 2.38-2.45 (m, 1H), 2.48-2.53 (d, 1H), 3.13-
3.19 (d, 1H), 3.86 (s, 3H), 3.99-4.08 (m, 4H), 6.20 (s, 1H), 6.95-6.98 (m, 2H), 
7.36-7.39 (m, 3H). 
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-
one (8c): 1H-NMR (CDCl3, 300.08 MHz) δ 1.24 (s, 3H), 1.59-1.79 (m, 2H), 2.03-
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2.13 (m, 1H), 2.40 (s, 3H), 2.49-2.70 (m, 3H), 2.90 (s, 2H), 6.32 (s, 1H), 7.26-
7.28 (m, 2H), 7.35-7.38 (m, 2H), 7.47 (s, 1H). 
1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-
carbaldehyde (10c): 1H-NMR (CDCl3, 300.08 MHz) δ 1.11 (s, 3H), 1.33-1.48 (m, 
1H), 1.65-1.80 (m, 1H), 1.88-1.96 (m, 2H), 2.32-2.45 (m, 3H), 2.85-2.92 (d, 1H), 
3.06-3.11 (d, 1H), 3.84 (s, 3H), 6.16 (s, 1H), 6.96-6.99 (m, 2H), 7.36-7.40 (m, 
3H), 9.89 (s, 1H). 
1-(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)ethan-1-ol (11ca): white solid obtained in 58% yield; mp 156-159 ˚C; TLC 
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.11; [α]D
20 = +25 (c 1.0, 
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.13 (s, 3H), 1.23-1.29 (m, 4H), 1.34-
1.45 (m, 3H), 1.74-1.78 (d, 1H),1.88-1.95 (d, 1H), 2.28-2.31 (d, 1H), 2.35-2.39 
(m, 1H), 2.47-2.51 (d, 1H), 2.98-3.01 (d, 1H), 3.84-3.87 (s, 3H), 6.10 (s, 1H), 
6.96-7.40 (m, 5H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.21, 20.80, 24.36, 25.85, 
33.31, 34.68, 41.16, 54.89, 55.49, 66.10, 109.38, 113.42, 114.25, 133.01, 
136.73, 137.32,149.51, 158.54; IR (NaCl, thin film) νmax (cm
-1): 3376 (OH), 3020 
(w), 2962, 2931, 2862, 1612, 1517, 1250, 831; HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C21H27N2O2, 339.20670; found 339.20344. 
2-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)propan-2-ol (13ca): white solid obtained in 58% yield; mp 
194-197 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.08; [α]D
20 = -
17 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 3H) 1.30-1.38 (d, 
6H), 1.48-1.55 (m, 1H), 1.66-1.69 (d, 1H), 1.76-1.87 (dd, 2H), 2.27-2.37 (m, 3H), 
2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 3.85 (s, 3H), 6.11 (s, 1H) 6.95-7.41 (m, 5H); 
13C-NMR (CDCl3, 125.66 MHz) δ 19.66, 26.38, 27.48, 28.39, 29.68, 33.91, 34.51, 
36.20, 43.60, 55.52, 57.61, 75.49, 109.57, 114.24, 114.96, 124.86, 133.10, 
136.29, 137.41, 150.90, 158.42; IR (NaCl, thin film) νmax (cm
-1): 3349 (OH), 3018, 
2928, 2857, 1612, 1517, 1248, 831; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for 




yl)(phenyl)methanol (11cb): beige solid obtained in 73% yield; mp 109.3-111.5 
˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.11; [α]D
20 = -10 (c 1.0, 
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 1.56-1.81 (m, 6H), 2.24-
2.27 (d, 1H), 2.36-2.44 (m, 1H), 2.75-2.78 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 
5.20 (s, 1H), 6.11 (s, 1H), 6.96-7.44 (m, 9H); 13C-NMR (CDCl3, 125.66 MHz) δ 
19.90, 25.78, 33.28, 35.23, 41.30, 56.65, 72.02, 114.27, 125.09, 125.36, 126.84, 
128.20, 132.99, 145.61, 149.62, 158.58; IR (NaCl, thin film) νmax (cm
-1): 3307 
(OH), 3056 (w), 2932, 2868, 2835, 1611, 1518, 1250, 833; HRMS (DART-RTOF) 
m/z: [M+H]+ Calcd for C26H29N2O2, 401.22235; found 401.21952. 
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)-1-phenylethan-1-ol (13cb): beige solid obtained in 100% 
yield, mp 105.1-108 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 
0.20; [α]D
20 = -30 (c 1.0, CHCl3); 
1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 
1.55-1.63 (m, 3H), 1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26 
(m, 1H), 2.33-2.38 (m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H), 
6.08 (s, 1H), 6.95-7.51 (m, 10H); 13C-NMR (CDCl3, 125.66 MHz) δ 20.43, 25.82, 
26.20, 28.38, 29.68, 34.19, 35.91, 44.03, 55.48, 56.79, 78.80, 109.33, 114.22, 
115.10, 125.55, 128.01, 133.11, 136.12, 137.46, 151.03, 158.39; IR (NaCl, thin 
film) νmax (cm
-1): 3338 (OH), 3020 (w), 2925, 2854, 1611, 1517, 1250, 833; 
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H31N2O2, 415.23800; found 
415.23680. 
(4-fluorophenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11cc): white solid obtained in 69% yield; mp 178-
182 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.26; [α]D
20 = +4 (c 
4.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.56-1.58 (m, 2H), 
1.66-1.70 (m, 2H), 1.79-1.82 (m, 1H), 2.25-2.28 (m, 1H), 2.37-2.40 (m, 1H), 2.73-
2.76 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 5.20 (d, 1H), 6.11 (s, 1H), 6.96-7.06 
(m, 4H), 7.30-7.44 (m, 5H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.84, 20.59, 
21.04, 25.80, 29.68, 33.28, 35.05, 41.22, 55.69, 69.85, 109.63, 113.56, 119.81, 
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123.50, 125.51, 126.00, 129.68, 137.60, 147.31, 149.4; IR (NaCl, thin film) νmax 
(cm-1): 3399 (OH), 2930, 2850, 1602, 1512, 1223, 824; HRMS (DART-RTOF) 
m/z: [M+H]+ Calcd for C26H28FN2O2, 419.21293; found 419.20660. 
1-(4-fluorophenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cc): white solid obtained in 49% 
yield; mp 182.1-185 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 
0.28; [α]D
20 = -51 (c 1.0, MeOH); 1H-NMR (CDCl3, 300.08 MHz) δ 1.25 (s, 3H), 
1.53-1.62 (m, 2H), 1.67 (s, 3H), 1.73-1.78 (m, 1H), 1.99-2.02 (d, 1H), 2.24-2.36 
(m, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 6.09 (s, 1H), 6.95-7.49 
(m, 9H); 13C-NMR (CDCl3, 499.73 MHz) δ 20.42, 25.82, 26.18, 28.46, 29.69, 
34.14, 36.05, 44.02, 55.53, 56.90, 78.55, 109.48, 114.23, 114.59, 114.76, 
124.84, 127.24, 136.09, 137.48, 151.60; IR (NaCl, thin film) νmax (cm
-1): 3363 
(OH), 2929, 2840, 1600, 1517, 1250, 834; HRMS (DART-RTOF) m/z: [M+H]+ 
Calcd for C27H30FN2O2, 433.22858; found 433.22897. 
(3,4-difluoro-5-methoxyphenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)methanol (11cd): white solid obtained in 71% 
yield, mp 174.1-177.4 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 
0.16; [α]D
20 = -50 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 
1.52-1.56 (m, 2H), 1.66-1.69 (m, 2H), 1.80-1.84 (m, 2H), 2.26-2.29 (m, 1H), 2.73-
2.76 (d, 1H), 3.15-3.18 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 5.12 (s, 1H), 6.11 (s, 
1H), 6.72-6.79 (m, 2H), 6.96-6.99 (m, 2H), 7.37-7.44 (m, 3H); 13C-NMR (CDCl3, 
125.66 MHz) δ 20.00, 25.70, 33.15, 35.35, 41.23, 55.54, 56.72, 71.34, 106.04, 
109.62, 113.09, 114.29, 125.09, 136.72, 137.36, 149.14, 158.65; IR (NaCl, thin 
film) νmax (cm
-1): 3400 (OH), 2930, 2868, 1611, 1517, 1250, 833; HRMS (DART-
RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O3, 467.21408; found 467.21488. 
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-
4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cd): white solid 
obtained in 65% yield, mp 184-187 ˚C, TLC (Silica G w/UV254) 30% EtOAc in 
hexanes, Rf = 0.13; [α]D
20 = +55 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 
1.26 (s, 3H), 1.60-1.67 (m, 6H) 1.79-1.82(d, 1H), 1.96-1.99 (d, 1H), 2.24-2.39 (m, 
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2H), 2.57-2.60 (d, 1H), 3.05-3.08 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 6.10 (s, 1H), 
6.87-7.01 (m, 4H), 7.32-7.45 (m, 3H); 13C-NMR (CDCl3, 125.66 MHz) δ 20.54, 
25.65, 26.24, 28.89, 33.95, 35.79, 44.05, 55.53, 56.35, 56.78, 106.27, 106.78, 
109.50, 114.25, 114.75, 124.85, 133.03, 137.42, 150.81; IR (NaCl, thin film) νmax 
(cm-1): 3329 (OH), 2932, 2850, 1622, 1518, 1251, 1100, 834; HRMS (DART-
RTOF) m/z: [M+H]+ Calcd for C27H30FN2O2, 433.22858; found 433.22897. 
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-2-yl)methanol (11ce): white solid obtained in 79% yield; mp 171-
173.6 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.17; [α]D
20 = -6.2 
(c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (m, 4H), 1.62-1.72 (m, 2H), 
1.77-1.85 (m, 2H), 2.27-2.41 (m, 2H), 2.69-2.72 (d, 1H), 3.12-3.15 (d, 1H), 3.85 
(s, 3H), 5.25 (s, 1H), 6.12 (s, 1H), 6.96-7.40 (m, 8H); 13C-NMR (CDCl3, 125.66 
MHz) δ 19.87, 20.59, 25.80, 33.28, 35.04, 41.26, 55.54, 55.69, 69.83, 109.44, 
113.31, 114.29, 119.82, 125.11, 125.51, 126.00, 137.26, 147.31, 158.65; IR 
(NaCl, thin film) νmax (cm
-1): 3310 (OH), 3090 (w), 2920, 2860, 1610 (w), 1519, 
1230, 830; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C24H27N2O2S, 407.1787; 
found 407.1720. 
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)-1-(thiophen-2-yl)ethan-1-ol (13ce): white solid obtained in 
48% yield; mp 146-148.5 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf 
= 0.16; [α]D
20 = +12 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ1.25 (s, 3H), 
1.59-1.65 (m, 2H), 1.68 (s, 3H), 1.73-1.78 (m, 2H), 2.03-2.06 (d, 1H), 2.25-2.36 
(m, 2H), 2.65-2.69 (d, 1H), 3.22-3.25 (d, 1H), 3.84 (s, 3H), 6.10 (s, 1H), 6.94-7.40 
(m, 8H); 13C-NMR (CDCl3, 125.66 MHz) δ 20.16, 26.16, 28.19, 34.31, 35.82, 
43.91, 55.48, 56.71, 77.52, 109.47, 114.23, 115.13, 119.72, 124.88, 126.51, 
133.11, 136.13, 137.47, 150.93, 152.99, 158.40; IR (NaCl, thin film) νmax (cm
-1): 
3365 (OH), 2930, 2850, 1610, 1517, 1250, 835; HRMS (ESI-RTOF) m/z: [M+H]+ 

















































































































































































LC Column: Synergi™ 2.5 µm Hydro-RP 100Å (100 x 2.0 mm) held at 40 
°C 
Mobile phase A (%C) – 0.1% formic acid in H2O 
Mobile phase B (%B) – 0.1% formic acid in ACN 
Flowrate – 300 µL/min 
MS Parameters: Scan mode – Full scan; Ionization mode – positive; AGC 
target – 3.0x106 ions; Max IT – 200 ms; Resolution – 140,000; Scan range 
– 150-500 m/z 
2.8.8 Non-steroidal glucocorticoid EICs and LCMS method for analysis of 
crude product 13ag 
An LCMS analysis of the crude product of the reaction of 12ag with 10 
equivalents of MeLi to determine the relative %-conversion of ketone 12ag to 3° 
OH 13ag. This was done to verify that under experimental conditions product 
13ag was not being produced from residual ketone 12ag that was produced as a 
byproduct from the previous reaction to make compound 11 analogues. 10 µL of 
a 50 µM solution of crude product 13ag was injected onto an analytical column 
and subjected to the chromatographic method described below.  




Mass spectrum under EIC of 12ag 
[M+H]+ calc’d for C23H28FN2O
+ = 367.2180 m/z; found – 367.2179 m/z; Δppm = -
0.27 
 
EIC – [M+H]+ 13ag  
RT: 0.00 - 20.52

















































Product12ag_13ag01_180628151209 #1225-1241 RT: 12.50-12.65 AV: 17 NL: 8.71E8
T: FTMS + p ESI Full ms [150.0000-500.0000]















































Mass spectrum under EIC of 13ag 
  
Far zoomed-in mass spectrum under 13ag EIC 
[M+H]+ calc’d for C24H32FN2O
+ = 383.2493 m/z; found – 383.2494 m/z; Δppm = 
0.21 
RT: 0.00 - 20.52

















































Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 1.17E7
T: FTMS + p ESI Full ms [150.0000-500.0000]



























































Relative abundance of 13ag to 12ag = 1.55x109 ions 12ag: 5.5x104 ions 13ag = 
~ 0.005 % conversion, without considering differences in ionization efficiencies 
between 12ag and 13ag. 
 
  
Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 1.63E5
T: FTMS + p ESI Full ms [150.0000-500.0000]





























































































































































































The work represented in the two chapters within the document display an 
interdisciplinary approach to solving real life issues that humans are dealing with 
today. Humans created the issue of dichloromethane byproducts ending up in the 
environment and causing drastic effects on the ecosystem and human health. 
The experiments that were done on the anaerobic bacteria give real hope that 
bioremediation of the toxic byproduct in the environment is very much possible. 
On the front of the side effects caused by the long term use of glucocorticoids, 
the molecules synthesized offer optimism that a dissociated steroid will be 
available on the drug market in the near future. Much progress has been made at 
expanding the literature on what we know about glucocorticoids, their structure-
activity relationship with the glucocorticoid receptor and reducing the harmful 
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